REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|
Emerging Growth Company
|
U.S. GAAP ☐
|
by the International Accounting Standards Board ☒ |
Other ☐
|
FORM 20-F
ANNUAL REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 |
i | |
i | |
1 | |
1 | |
1 | |
40 | |
87 | |
87 | |
99 | |
119 | |
123 | |
124 | |
125 | |
134 | |
135 | |
135 | |
136 | |
136 | |
136 | |
136 | |
137 | |
137 | |
137 | |
137 | |
138 | |
138 | |
138 | |
138 | |
138 | |
139 | |
142 |
• |
our commercialization, marketing and manufacturing capabilities and strategy and the
ability of our marketing team to cover European regional burn centers and units; | |
• |
the timing and conduct of our trials of NexoBrid, EscharEx and our other pipeline
product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical
trials, and our research and development programs; | |
• |
the clinical utility, potential advantages and timing or likelihood of regulatory
filings and approvals of EscharEx and our other pipeline products; | |
• |
our expectations regarding future growth, including our ability to develop new products;
| |
• |
our estimates regarding expenses, future revenues, capital requirements and our need
for additional financing; |
• |
anticipated funding under our contracts with the U.S. Biomedical Advanced Research
and Development Authority; |
• |
our ability to maintain adequate protection of our intellectual property; |
|
• |
our estimates regarding the market opportunity for NexoBrid, EscharEx and our other
pipeline products; | |
• |
our expectation regarding the duration of our inventory of intermediate drug substances
and products; | |
• |
the impact of our research and development expenses as we continue developing product
candidates; and | |
• |
the impact of government laws and regulations. |
Item 1. |
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS |
Item 2. |
OFFER STATISTICS AND EXPECTED TIMETABLE |
Item 3. |
KEY INFORMATION |
|
A. |
[Reserved] |
|
B. |
Capitalization and Indebtedness |
|
C. |
Reasons for the Offer and Use of Proceeds |
|
D. |
Risk Factors |
|
• |
regulators may not authorize us to conduct a clinical trial within a country or at
a prospective trial site or may require us to change the design of a study;
|
|
• |
delays may occur in reaching agreement on acceptable clinical trial terms with regulatory
authorities or prospective sites, or obtaining institutional review board or ethics committee approval or opinion;
|
|
• |
our preclinical tests or clinical trials may produce negative or inconclusive results,
and we may decide, or regulators may require us, to conduct additional trials or to abandon strategic projects;
|
|
• |
the number of patients required for our clinical trials may be larger than we anticipate,
enrollment in our clinical trials may be slower or more difficult than we expect, or patients may not participate in necessary follow-up
visits to obtain required data, any of which would result in significant delays in our clinical testing process;
|
|
• |
our third-party contractors, such as a research institute, may fail to comply with
regulatory requirements or meet their contractual obligations to us;
|
|
• |
we may be forced to suspend or terminate our clinical trials if the participants are
being exposed, or are thought to be exposed, to unacceptable health risks or if any participant experiences an unexpected serious adverse
event;
|
|
• |
regulators or institutional review boards may require that we hold, suspend or terminate
clinical research for various reasons, including noncompliance with regulatory requirements;
|
|
• |
undetected or concealed fraudulent activity by a clinical researcher, if discovered,
could preclude the submission of clinical data prepared by that researcher, lead to the suspension or substantive scientific review of
one or more of our marketing applications by regulatory agencies, and result in the recall of any approved product distributed pursuant
to data determined to be fraudulent;
|
|
• |
the cost of our clinical trials may be greater than we anticipate;
|
|
• |
an audit of preclinical or clinical studies by regulatory authorities may reveal noncompliance
with applicable protocols or regulations, which could lead to disqualification of the results and the need to perform additional studies;
|
|
• |
political unrest and wars, such as the conflict between Russia and Ukraine, which
could delay or disrupt business activity, and if such political unrest escalates or spills over to or otherwise impacts additional regions,
it could also heighten many of the other risk factors described in this Annual Report;
|
|
• |
delays may occur in obtaining our clinical materials; and
|
|
• |
epidemics or pandemics, such as the COVID-19 pandemic that can affect the overall
healthcare infrastructure, including the ability to recruit patients, the ability to conduct studies at medical sites and the pace with
which governmental agencies, such as the FDA and foreign regulatory authorities, will review and approve regulatory submissions.
|
|
• |
restrictions on the marketing or manufacturing of the product, withdrawal of the product
from the market or voluntary or mandatory product recalls; |
|
• |
fines, warning letters or holds on clinical trials; |
|
• |
harm to our reputation, reduced demand for our products and loss of market acceptance;
|
|
• |
refusal by the applicable regulatory authority to approve pending applications or
supplements to approved applications filed by us, or suspension or revocation of product license approvals; |
|
• |
product seizure or detention, or refusal to permit the import or export of products;
and |
|
• |
injunctions or the imposition of civil or criminal penalties. |
• |
the willingness of physicians, burn care teams and hospital administrators to administer
our products and the acceptance of our products as part of the medical department routine; |
|
• |
the consent of hospitals to fund/purchase NexoBrid or obtain third-party coverage
or reimbursement for our products; |
|
• |
the ability to offer NexoBrid, EscharEx and our pipeline product candidates for sale
at an attractive value; |
|
• |
the efficacy and potential advantages of NexoBrid, EscharEx and our pipeline product
candidates relative to current standard of care; |
• |
the prevalence and severity of any side effects; and |
|
• |
the efficacy, potential advantages and timing of introduction to the market of alternative
treatments. |
|
• |
the market acceptance or demand for NexoBrid, EscharEx or any of our pipeline product
candidates, if approved; |
|
• |
the ability to set a price that we believe is fair for NexoBrid, EscharEx or any of
our pipeline product candidates, if approved; |
|
• |
our ability to generate revenues and achieve or maintain profitability; |
|
• |
the level of taxes that we are required to pay; and |
|
• |
the availability of capital. |
|
• |
an annual, nondeductible fee on any entity that manufactures or imports certain branded
prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare
programs; |
|
• |
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid
Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively; |
|
• |
addressed a new methodology by which rebates owed by manufacturers under the Medicaid
Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; |
|
• |
a new Medicare Part D coverage gap discount program, in which manufacturers must agree
to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap
period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; |
|
• |
extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed
to individuals who are enrolled in Medicaid managed care organizations; |
|
• |
expansion of eligibility criteria for Medicaid programs by, among other things, allowing
states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals
with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
|
|
• |
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical
pricing program; |
• |
a new requirement to annually report drug samples that manufacturers and distributors
provide to physicians; and |
|
• |
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities
in, and conduct comparative clinical effectiveness research. |
|
• |
accelerate our clinical development activities, particularly with respect to our clinical
development of EscharEx for the debridement of chronic and other hard-to-heal wounds and our clinical trials for our other pipeline product
candidates; |
|
• |
further scale-up the manufacturing process for NexoBrid; |
|
• |
seek regulatory and marketing authorizations for our products and any pipeline product
candidate that successfully completes clinical trials; |
|
• |
initiate additional preclinical, clinical or other studies for NexoBrid, EscharEx
and our pipeline product candidates, and seek to identify and validate new products; |
|
• |
commercialize NexoBrid and any pipeline product candidates for which we obtain marketing
authorization; |
|
• |
acquire rights to other product candidates and technologies; |
|
• |
change or add suppliers; |
|
• |
maintain, expand and protect our intellectual property portfolio; |
|
• |
attract and retain skilled personnel; and |
|
• |
experience any delays or encounter issues with any of the above. |
|
• |
delay, scale back or discontinue the development, manufacturing scale-up or commercialization
of NexoBrid, EscharEx or our pipeline product candidates;
|
|
• |
seek additional corporate partners for NexoBrid, EscharEx or one or more of our pipeline
product candidates on terms that are less favorable than might otherwise be available; or
|
|
• |
relinquish or license to additional parties, on unfavorable terms, our rights to NexoBrid,
EscharEx or our pipeline product candidates that we otherwise would seek to develop or commercialize ourselves.
|
|
• |
any such consequence will have a material adverse effect on our business, operating
results and prospects and on our ability to develop our pipeline product candidates.
|
|
• |
the Federal Acquisition Regulations (“FAR”) and agency-specific regulations
supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;
|
|
• |
business ethics and public integrity obligations, which govern conflicts of interest
and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other
requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;
|
|
• |
export and import control laws and regulations; and
|
|
• |
laws, regulations and executive orders restricting the use and dissemination of information
classified for national security purposes and the exportation of certain products and technical data. |
|
• |
any of our present or future patents or patent claims or other intellectual property
rights will not lapse or be invalidated, circumvented, challenged or abandoned;
|
|
• |
our intellectual property rights will provide competitive advantages or prevent competitors
from making or selling competing products; |
|
• |
our ability to assert our intellectual property rights against potential competitors
or to settle current or future disputes will not be limited by our agreements with third parties;
|
|
• |
any of our pending or future patent applications will be issued or have the coverage
originally sought;
|
|
• |
our intellectual property rights will be enforced in jurisdictions where competition
may be intense or where legal protection may be weak; or
|
|
• |
we will not lose the ability to assert our intellectual property rights against, or
to license our technology to, others and collect royalties or other payments. |
|
• |
actual or anticipated variations in our and our competitors’ results of operations
and financial condition;
|
|
• |
market acceptance of our products;
|
|
• |
general economic and market conditions and other factors, including factors unrelated
to our operating performance;
|
|
• |
the mix of products that we sell and related services that we provide;
|
|
• |
changes in earnings estimates or recommendations by securities analysts, if our ordinary
shares continue to be covered by analysts; |
|
• |
publication of the results of preclinical or clinical trials for NexoBrid, EscharEx
or any of our pipeline product candidates; |
|
• |
failure by us to achieve a publicly announced milestone;
|
|
• |
delays between our expenditures to develop and market new or enhanced products and
the generation of sales from those products; |
|
• |
development of technological innovations or new competitive products by others;
|
|
• |
announcements of technological innovations or new products by us;
|
|
• |
regulatory developments and the decisions of regulatory authorities as to the marketing
of our current products or the approval or rejection of new or modified products;
|
|
• |
developments concerning intellectual property rights, including our involvement in
litigation;
|
|
• |
changes in our expenditures to develop, acquire or license new products, technologies
or businesses;
|
|
• |
changes in our expenditures to promote our products; |
|
• |
changes in the structure of healthcare payment systems;
|
|
• |
our sale or proposed sale, or the sale by our significant shareholders, of our ordinary
shares or other securities in the future; |
|
• |
changes in key personnel;
|
|
• |
success or failure of our research and development projects or those of our competitors;
and
|
|
• |
the trading volume of our ordinary shares. |
A. |
History and Development of the Company |
|
B. |
Business Overview |
|
• |
The extent of the surface that the burn occupies is usually referred to as percent
of total body surface area (“TBSA”). A burn on an adult’s entire palm would generally amount to 1% TBSA, and the average
hospitalized patient has a burn covering approximately 9% TBSA. Burns covering more than 15-20% TBSA usually require hospitalization and
may result in dehydration, shock and increased risk of mortality.
|
|
• |
The depth of the burn, referred to in terms of “degree” is generally classified into four categories:
|
|
○ |
Superficial or first-degree burns. Such burns
do not penetrate the basal membrane and usually heal naturally.
|
|
○ |
Dermal/partial thickness or second-degree burns.
Such burns are characterized by varying amounts of damaged dermis and can be further subdivided into superficial and deep partial-thickness
burns. Superficial partial-thickness burns may heal spontaneously after removal of the covering thin eschar. Conversely, deep partial-thickness
burns are often difficult for physicians to accurately diagnose before eschar removal and may progress and transform into full-thickness
burns if not debrided in a timely manner, depending on the magnitude of latent tissue death of the surrounding skin.
|
|
○ |
Full thickness or third-degree burns. Such
burns are characterized by death of the entire dermal tissue down to the subcutaneous fat and must be debrided and treated by autografting,
which is the process of harvesting skin from healthy donor sites on a patient’s body and transplanting it on the post-debridement,
clean wound bed.
|
|
○ |
Fourth-degree burns. Such burns, which are
rare, extend beyond the subcutaneous fat tissue into the underlying structures, such as muscle or bone, and also require debridement and
further substantial treatment.
|
|
• |
Other factors include the age of the victim, the body part where the burn occurred
and any co-morbidities of the patient. For example, some patients may require hospitalization regardless of the TBSA or degree of the
burn, such as children, the elderly or victims with burns to the extremities, joints or head/neck area or with co-morbidities such as
smoke inhalation, diabetes or obesity.
|
|
• |
the prevention of local infection, sepsis (a systemic inflammatory response caused
by severe infection) and additional damage to surrounding viable tissue; and
|
|
• |
the initiation of the body’s healing process and scar prevention.
|
|
• |
Surgical debridement
|
|
○ |
Surgical debridement predominantly includes tangential excision, a procedure in which
a surgeon amputates the entire dead tissue mass, layer after layer, down to healthy, viable tissue. The excision is extended into healthy
intact tissue to make sure that no trace of the eschar remains, resulting in up to an estimated 30-50% of healthy tissue being excised
during this procedure. Other methods include dermabrasion, in which a mechanically powered, hand-held rotating abrading cylinder is used
to slowly scrape off tissue, and hydro surgery, in which a high-pressure flow of water abrades the tissue. These alternative methods have
attempted to limit the trauma associated with tangential excision, but entail spray of contaminated eschar or take a significantly longer
time to complete than tangential excision. |
|
○ |
The benefits of surgical eschar removal are that it is usually fast and effective.
Disadvantages include the significant trauma of the procedure, associated blood loss, risk of surgery in delicate areas of the body such
as hands, added costs, and, most importantly, the loss of viable tissue that necessitates additional surgical procedures for harvesting
skin from healthy donor sites and autografting. |
|
○ |
Due to the disadvantages of surgery in extensive burns some surgeons limit their debriding
surgery to only a part of the affected area in a single session (15-30% TBSA in most centers), thus delaying full debridement by days.
After several days, complications related to eschar contamination may begin and some of the benefits of the earlier debridement may not
be realized. On the other hand, when excising burns immediately, all suspected necrotic tissue will be excised, inevitably resulting in
over-excision, especially in “indeterminate” burns, as after surgical excision, the remaining skin often no longer has any
spontaneous healing potential and will heal only by autografting. |
|
• |
Non-surgical debridement
|
|
○ |
Non-surgical debridement includes many different treatment options that do not require
direct surgical removal of the skin to remove eschar. With non-surgical debridement, the eschar is naturally, but slowly, removed by contaminant
microorganisms, tissue autolysis, or self-decomposition, and the inflammatory process that may lead to serious local and systemic complications.
In seeking to facilitate such natural processes, topical medication, anti-microbial agents, enzymes and biological/chemical applications
are often applied onto the eschar.
|
|
○ |
The benefits of this approach are that it is non-surgical, reduces trauma to the patient
and is easier to apply. Disadvantages include numerous dressing changes and mechanical scraping with limited debridement efficacy. This
prolongs the eschar removal process, which may lead to death of the tissue surrounding the initial burn wound, causing partial-thickness
wounds to transform into full-thickness wounds and forming granulation tissue that may develop into heavy scars.
|
|
Trial 1
|
Trial 2
|
Trial 3
|
Trial 4
|
Trial 5
|
Trial 6
|
Trial 7
|
Trial 8
|
Trial 9
|
Study Type
|
Retrospective Phase II
Investigator initiated
|
Dose range Phase II
|
Prospective Phase II
IND/FDA
|
Phase II
IND/FDA
|
Phase III
EMA
|
Phase IIIb
EMA
|
Phase II
EMA
|
Post approval safety study
EMA
|
Phase III
IND/FDA
|
Design
|
Data collected from files of patients treated with NexoBrid
|
Parallel, controlled, observer-
blind, randomized, single-center |
Parallel, controlled, observer-
blind, three-arm, randomized, multi-center |
Parallel, controlled, open label, three-arm, randomized, single-center
|
Parallel, controlled, open label, two-arm, randomized, multi-center
|
Parallel, controlled, blinded, two-arm, multi-center
|
Open label,
single-arm, multi-center |
Observational retrospective data collection
|
Parallel, controlled, open label, three-arm, randomized, multi-center
|
Main Objectives
|
Safety and efficacy
|
Comparison of efficacy and safety
|
Safety and efficacy
|
Safety
|
Safety
Efficacy
|
Long-term scar assessment
Quality of life
|
Safety and pharmacokinetics
Efficacy
|
Effectiveness of the risk minimization activities
|
Safety
Efficacy
|
Wound Types
|
Deep partial/full thickness thermal burns
|
Deep partial /full thickness thermal burns
|
Deep partial /full thickness thermal burns
|
Deep partial /full thickness thermal burns
|
Deep partial/ full thickness thermal burns
|
Scar formation
|
Deep partial/full thickness thermal burns
|
Burns which were treated with NexoBrid in the market
|
Deep partial/ full thickness thermal burns
|
Number of Patients
|
154
|
20
|
140
|
30
|
182
|
89
|
36
|
160
|
175
|
Study Length
|
1985-2000
|
2002-2005
|
2003-2004
|
2006-2007
|
2006-2009
|
2011
|
2009-2015
|
2017-2019
|
2015-2020
|
Location
|
Israel
|
Israel
|
International
|
United States
|
International
|
International
|
International
|
Europe
|
International
|
|
• |
Venous leg ulcers. VLUs develop as a
result of vascular insufficiency, or the inability for the vasculature of the leg to return blood back toward the heart properly. Based
on our comprehensive market research study on EscharEx that involved more than 200 healthcare professionals in the U.S. and Europe, which
was last updated in 2022, the VLU overall prevalence is approximately 3.3 million (1% of total U.S. population). Furthermore, the annual
incidence of VLUs in the U.S. alone, is approximately 960,000 (accounting for 45% recurrence), of which approximately 690,000 undergo
debridement in a given year. These ulcers usually form on the sides of the lower leg, above the ankle and below the calf, and are
slow to heal and often recur if preventative steps are not taken. The risk of VLUs can increase as a result of a blood clot forming in
the deep veins of the legs, obesity, smoking, lack of physical activity or work that requires many hours of standing. |
|
• |
Diabetic foot ulcers. Diabetes can lead
to a reduction in blood flow, which can cause patients to lose sensation in their feet and may prevent them from noticing injuries, sometimes
leading to the development of DFUs, which are open sores or ulcers on the feet that may take several weeks to heal, if ever. Based
on our comprehensive market research study conducted in 2015 on EscharEx that involved more than 200 healthcare professionals in the U.S.
and Europe and, which was updated in 2019, there are estimated 31 million diabetics in 2019 (9.4% of the U.S. population). The annual
incidence of DFUs in the United States alone, is approximately 990,000 (accounting for 45% recurrence), of which approximately 820,000
undergo debridement in a given year. |
|
• |
Pressure ulcers. Pressure ulcers
form as a result of pressure sores, or bed sores, which are injuries to the skin or the tissue beneath the skin. Constant pressure on
an area of skin reduces blood supply to the area and over time can cause the skin to break down and form an open ulcer. These often
occur in patients who are hospitalized or confined to a chair or bed, and usually form over bony areas, where there is little cushion
between the bone and the skin, such as lower parts of the body. Annually, 2.5 million pressure ulcers are treated in the United
States in acute care facilities alone. |
|
• |
Surgical/traumatic wounds. Surgical wounds
form as a result of various types of surgical procedures such as investigative or corrective, minor or major, open (traditional) or minimal
access surgery, elective or emergency, and incisions (simple cuts) or excision (removal of tissue), among others. Traumatic wounds form
as a result of cuts, lacerations or puncture wounds, which have caused damage to the skin and underlying tissue. Severe traumatic wounds
may require surgical intervention to close the wound and stabilize the patient. Surgical/traumatic hard-to-heal wounds develop for various
reasons, such as local surgical complications, suboptimal closure techniques, presence of foreign materials, exposed bones or tendons
and infection. In the United States, millions receive post-surgical wound care annually. |
|
• |
Basal cell carcinomas - BCC starts in the basal cell layer, which is the lower part
of the epidermis. If not removed completely, basal cell carcinoma can come back (recur) in the same place on the skin. People who
have had basal cell skin cancers are also more likely to get new ones in other places. BCCs are uncontrolled and abnormal growths that
arise in the basal cells of the skin and the tumors primarily affect photo exposed areas, most commonly in the head, and infrequently
appear on unexposed areas such as the genital and genitalia regions. The main cause of BCC is chronic ultraviolet (UV) exposure. BCC is
the most common form of skin cancer, accounting for 75-80% of all skin cancers
|
|
• |
Squamous cell carcinomas - Squamous cell carcinomas (“SCC”) start in the
flat cells in the upper (outer) part of the epidermis |
|
• |
Actinic keratosis - Actinic keratosis (“AK”), also known as solar keratosis,
is a pre-cancerous skin condition caused by too much exposure to the sun. People who have them usually develop more than one. A small
percentage of AKs may turn into squamous cell skin cancer.
|
|
• |
Bowen disease - Bowen disease (squamous cell carcinoma in situ), is the earliest form
of squamous cell skin cancer
|
|
• |
laboratory tests, animal studies and formulation studies all performed in accordance
with the applicable EU GLP or GMP regulations; |
|
• |
submission to the relevant authorities of a CTA, which must be approved before human
clinical trials may begin;
|
|
• |
performance of adequate and well‑controlled clinical trials to establish the
safety and efficacy of the product for each proposed indication;
|
|
• |
submission to the relevant competent authorities of a marketing authorization application
(“MAA”), which includes the data supporting preclinical and clinical safety and efficacy as well as detailed information on
the manufacture and composition and control of the product development and proposed labeling as well as other information; |
|
• |
inspection by the relevant national authorities of the manufacturing facility or facilities
and quality systems (including those of third parties) at which the product is produced, to assess compliance with strictly enforced GMP;
|
|
• |
potential audits of the non‑clinical and clinical trial sites that generated
the data in support of the MAA; and
|
|
• |
review and approval by the relevant competent authority of the MAA before any commercial
marketing, sale or shipment of the product. |
|
• |
Phase I (Most typical kind of study: Human Pharmacology);
|
|
• |
Phase II (Most typical kind of study: Therapeutic Exploratory);
|
|
• |
Phase III (Most typical kind of study: Therapeutic Confirmatory); and
|
|
• |
Phase IV (Variety of Studies: Therapeutic Use).
|
|
• |
medicines that have been authorized for marketing in the EU with the results of PIP
studies included in the product information are eligible for an extension of their supplementary protection certificate extension (if
any is in effect at the time of approval) by six months. This is the case even when the studies’ results are negative;
|
|
• |
for orphan medicines, such as NexoBrid, the incentive is an additional two years of
market exclusivity instead of one;
|
|
• |
scientific advice and protocol assistance at the EMA are free of charge for questions
relating to the development of medicines for children; and
|
|
• |
medicines developed specifically for children that are already authorized, but are
not protected by a patent or supplementary protection certificate, can apply for a pediatric use marketing authorization (“PUMA”).
If a PUMA is granted, the product will benefit from 10 years of market protection as an incentive.
|
|
• |
Mutual recognition procedure. If an authorization
has been granted by one-member state, or the Reference Member State, an application may be made for mutual recognition in one or more
other member states, or the Concerned Member State(s).
|
|
• |
Decentralized procedure. The decentralized
procedure may be used to obtain a marketing authorization in several European member states when the applicant does not yet have a marketing
authorization in any country.
|
|
• |
National procedure. Applicants following the
national procedure will be granted a marketing authorization that is valid only in a single member state. Furthermore, this marketing
authorization is not based on recognition of another marketing authorization for the same product awarded by an assessment authority of
another member state. If marketing authorization in only one-member state is preferred, an application can be filed with the national
competent authority of a member state. The national procedure can also serve as the first phase of a mutual recognition procedure.
|
|
• |
completion of laboratory tests, animal studies and formulation studies in compliance
with the FDA’s GLP and GMP regulations, as applicable;
|
|
• |
submission to the FDA of an investigational new drug application (“IND”),
which must become effective before clinical trials may begin;
|
|
• |
approval by an independent institutional review board (“IRB”) at each
clinical site before each trial may be initiated; |
|
• |
performance of adequate and well‑controlled clinical trials in accordance with
GCP to establish the safety and efficacy of the product for each indication;
|
|
• |
preparation and submission to the FDA of a BLA;
|
|
• |
satisfactory completion of an FDA advisory committee review, if applicable;
|
|
• |
satisfactory completion of one or more FDA inspections of the manufacturing facility
or facilities at which the product, or components thereof, are produced to assess compliance with cGMP requirements, and to assure that
the facilities, methods and controls are adequate to preserve the product’s safety, purity and potency, and of selected clinical
investigation sites to assess compliance with GCP; and
|
|
• |
payment of user fees and FDA review and approval of the BLA to permit commercial marketing
of the product for particular indications for use in the United States.
|
Phase I: |
The investigational product is initially introduced into healthy human subjects or
patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion
and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.
|
Phase II: |
The investigational product is administered to a limited patient population to identify
possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to
determine dosage tolerance and optimal dosage.
|
Phase III: |
The investigational product is administered to an expanded patient population, generally
at geographically dispersed clinical trial sites, in well‑controlled clinical trials to generate enough data to statistically evaluate
the efficacy and safety of the product for approval, to establish the overall risk‑benefit profile of the product, and to provide
adequate information for the labeling of the product. |
|
• |
increases the minimum level of Medicaid rebates payable by manufacturers of brand‑name
drugs from 15.1% to 23.1%;
|
|
• |
requires collection of rebates for drugs paid by Medicaid managed care organizations;
and
|
|
• |
imposes a non‑deductible annual fee on pharmaceutical manufacturers or importers
who sell certain “branded prescription drugs” to specified federal government programs. |
|
• |
the federal healthcare Anti‑Kickback Statute prohibits, among other things,
persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in
kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service for
which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does
not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;
|
|
• |
the federal False Claims Act imposes civil penalties, and provides for civil whistleblower
or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims
for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal
government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;
|
|
• |
HIPAA, imposes criminal and civil liability for executing a scheme to defraud any
healthcare benefit program or making false statements relating to healthcare matters;
|
|
• |
the federal false statements statute prohibits knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare
benefits, items or services;
|
|
• |
the federal physician payment transparency requirements under the Affordable Care
Act require certain manufacturers of drugs, devices and medical supplies to report to Centers for Medicare & Medicaid Services information
related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors),
certain other non-physician practitioners such as physician assistants and nurse practitioners, and teaching hospitals and physician ownership
and investment interests;
|
|
• |
analogous state and foreign laws and regulations, such as state anti‑kickback
and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non‑governmental
third‑party payors, including private insurers.
|
Years Ended December 31, |
||||||||
2022 |
2021 | |||||||
(in thousands) |
||||||||
Condensed statements of operations data:
|
||||||||
Revenues |
$ |
26,496 |
$ |
23,763 |
||||
Cost of revenues
|
13,331 |
14,992
|
||||||
Gross profit
|
13,165 |
8,771
|
||||||
Operating expenses: |
||||||||
Research and development
|
10,181 |
10,256
|
||||||
Selling and marketing
|
3,725 |
3,388
|
||||||
General and administrative
|
6,920 |
6,348
|
||||||
684 |
- |
|||||||
Other expenses |
||||||||
Operating loss
|
(8,345 |
) |
(11,221 |
) | ||||
Financial expenses, net
|
(11,176 |
) |
(2,303 |
) | ||||
Loss before taxes on income
|
(19,521 |
) |
(13,524 |
) | ||||
Tax expenses |
(78 |
) |
(27 |
) | ||||
Net loss
|
$ |
(19,599 |
) |
$ |
(13,551 |
) |
Years Ended December 31, |
||||||||
2022 |
2021 | |||||||
(in thousands) |
||||||||
Revenues from sale of products |
$ |
5,347 |
$ |
9,613 |
||||
Revenues from development services |
12,943 |
12,372
|
||||||
Revenues from license agreements |
8,206 |
1,778
|
||||||
|
26,496 |
23,763
|
Years Ended December 31, |
||||||||
2022 |
2021 |
|||||||
(in thousands) |
||||||||
International (excluding U.S.) |
$ |
4,624 |
$ |
5,661 |
||||
U.S. |
21,872 |
18,102 |
||||||
|
26,496 |
23,718 |
Years Ended December 31, |
||||||||
2022 |
2021 |
|||||||
(in thousands) |
||||||||
Cost of revenues from sales of products |
$ |
3,184 |
$ |
4,983 |
||||
Cost of revenues from development services |
9,829 |
9,907
|
||||||
Cost of revenues from license agreements |
318 |
102
|
||||||
|
13,331 |
14,992
|
Financial income, net |
Years Ended December 31,
|
|||||||
|
2022
|
2021 |
||||||
|
(in thousands)
|
|||||||
Financial income |
$ |
461 |
$ |
11 |
||||
Financial expenses |
(11,637 |
) |
(2,314 |
) | ||||
|
(11,176 |
) |
(2,303 |
) |
|
Year Ended December 31,
|
|||||||
|
2022
|
2021
|
||||||
|
||||||||
Net cash provided by (used in): |
||||||||
Operating activities
|
$ |
(11,885 |
) |
$ |
(8,916 |
) | ||
Investing activities
|
(481 |
) |
3,548 |
| ||||
Financing activities
|
35,764 |
|
(1,050 |
) |
|
• |
amortization of the cost of purchased a patent, rights to use a patent, and know-how,
which are used for the development or advancement of the Industrial Enterprise, over an eight-year period, commencing on the year in which
such rights were first exercised; |
|
• |
under limited conditions, an election to file consolidated tax returns with related
Israeli Industrial Companies controlled by it; and
|
|
• |
expenses related to a public offering are deductible in equal amounts over a three
years period commencing on the year of the offering. |
• |
further actions taken by central banks in Europe and the U.S. to increase interest rates as a means to slow down inflation,
which may worsen credit/financing conditions for our customers who purchase our products; |
• |
potential contraction of economic activities and recessionary conditions that could arise as a result of interest rate increases
and a decrease in consumer demand; and |
• |
the continued depreciated value of the Euro relative to the U.S. dollar, which may have an adverse impact on the U.S.- denominated
value of our European-derived revenues for purposes of our financial statements. |
Name |
|
Age |
|
Position |
Executive Officers |
|
|
|
|
Ofer Gonen |
|
50 |
|
Chief Executive Officer |
Boaz Gur-Lavie |
|
49 |
|
Chief Financial Officer |
Ety Klinger Ph.D. |
|
61 |
|
Chief Research and Development Officer |
Robert Snyder |
73 |
Chief Medical Officer | ||
Tzvi Palash |
67 |
Chief Operations Officer | ||
Yaron Meyer |
|
44 |
|
Executive Vice President, General Counsel and Corporate Secretary |
|
|
|
|
|
Directors |
|
|
||
Nachum (Homi) Shamir (3)(5) |
|
68 |
|
Executive Chairman of the Board of Directors |
Stephen T. Willis (1)(2)(4)(5) |
|
66 |
|
Director |
Assaf Segal |
|
51 |
|
Director |
Vickie R. Driver, M.D (4)(5) |
|
69 |
|
Director |
Nissim Mashiach (1)(2)(5) |
|
62 |
|
Director |
Sharon Kochan (1)(2)(5) |
|
54 |
|
Director |
David Fox (3)(5) |
|
65 |
|
Director |
Sharon Malka (4) |
|
51 |
|
Director |
|
|
(1) |
Member of our audit committee. |
(2) |
Member of our compensation committee.
|
(3) |
Member of our nominating, governance
and sustainability committee. |
(4) |
Member of our research and development
committee. |
(5) |
Independent director under the listing rules of the Nasdaq Stock Market. |
Name and Position |
Salary & Social Benefits(1) |
Bonus
|
Share‑Based Payment(2) |
Other Compensation(3)
|
Total
|
||||||||||
|
( thousand U.S. dollars)(4) |
||||||||||||||
|
|||||||||||||||
Sharon Malka, Director and
former CEO(5) |
308 |
- |
345 |
316 |
969 |
||||||||||
Ofer Gonen, Chief Executive
Officer |
253 |
200 |
365 |
32 |
850 |
||||||||||
Lior Rosenberg, M.D., Chief Medical Technology Officer |
324 |
167 |
90 |
236 |
817 |
||||||||||
Ety Klinger, Chief Research & Development Officer |
298 |
75 |
77 |
20 |
470 |
||||||||||
Boaz Gur-Lavie, Chief Financial
Officer |
255 |
60 |
76 |
18 |
409 |
|
|
(1) |
Represents the officer’s gross salary plus payment of mandatory social benefits
made by the company on behalf of such officer. Such benefits may include, to the extent applicable to the executive, payments, contributions
and/or allocations for savings funds (e.g., Managers’ Life Insurance Policy), education funds (referred to in Hebrew as “keren
hishtalmut”), pension, severance, risk insurances (e.g., life or work disability insurance) and payments for social security.
|
(2) |
Represents the equity‑based compensation expenses recorded in the company’s
consolidated financial statements for the year ended December 31, 2022 based on the options’ grant date fair value in accordance
with accounting guidance for equity‑based compensation.
|
(3) |
Represents the other benefits to such officer, which includes either or both of (i)
car expenses, including lease costs, gas and maintenance, provided to the officers, (ii) vacation benefits and (iii) severance payment.
|
(4) |
Converted (i) from NIS into U.S. dollars at the rate of NIS 3.358 = U.S$1, based on
the average representative rate of exchange between the NIS and the U.S. dollar in the year ended December 31, 2022 as reported by the
Bank of Israel in the year ended December 31, 2022.
|
(5) |
The compensation received by Mr. Malka in respect of the year ended December 31, 2022
consists of compensation that he received as our CEO until June 30, 2022 and cash, equity awards and other compensation that he received
in his role as active director commencing in July 2022. |
|
Number of |
Number of |
Exercise |
Vested |
| |||||||||
Name |
Options |
RSUs |
Grant Date |
Price - $ |
Options/RSU's |
Expiration Date |
||||||||
Sharon Malka |
17,371 |
24/12/2013 |
90.23 |
17,371 |
22/12/2023 | |||||||||
7,142 |
23/12/2015 |
67.06 |
7,142 |
20/12/2025 | ||||||||||
|
19,285 |
31/12/2018 |
36.05 |
19,285 |
28/12/2028 | |||||||||
5,714 |
24/03/2019 |
34.44 |
4,286 |
21/03/2029 | ||||||||||
|
11,595 |
23/04/2020 |
12.25 |
5,798 |
21/04/2030 | |||||||||
6,527 |
04/03/2021 |
37.52 |
3,264 |
02/03/2031 | ||||||||||
|
28,572 |
07/06/2022 |
14.42 |
21,428 |
04/06/2032 | |||||||||
6,428 |
31/12/2018 |
0 |
6,428 |
28/12/2028 | ||||||||||
|
2,857 |
24/03/2019 |
0 |
2,142 |
21/03/2029 | |||||||||
1,087 |
04/03/2021 |
0 |
544 |
02/03/2031 | ||||||||||
3,571 |
07/06/2022 |
0 |
2,678 |
04/06/2032 |
|
• |
oversight of our independent registered public accounting firm and recommending the
engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in
accordance with Israeli law; |
|
• |
recommending the engagement or termination of the person filling the office of our
internal auditor; and
|
|
• |
recommending the terms of audit and non‑audit services provided by the independent
registered public accounting firm for pre‑approval by our board of directors. |
|
• |
determining whether there are deficiencies in the business management practices of
our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of
directors to improve such practices;
|
|
• |
determining whether to approve certain related party transactions (including transactions
in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli Companies
Law) (see “—Approval of Related Party Transactions Under Israeli Law”);
|
|
• |
establishing the approval process (including, potentially, the approval of the audit
committee and conducting a competitive procedure supervised by the audit committee) for certain transactions with a controlling shareholder
or in which a controlling shareholder has a personal interest;
|
|
• |
where the board of directors approves the working plan of the internal auditor, examining
such working plan before its submission to the board of directors and proposing amendments thereto;
|
|
• |
examining our internal audit controls and internal auditor’s performance, including
whether the internal auditor has sufficient resources and tools to fulfill his responsibilities;
|
|
• |
examining the scope of our auditor’s work and compensation and submitting a
recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment
of our auditor; and
|
|
• |
establishing procedures for the handling of employees’ complaints as to the
management of our business and the protection to be provided to such employees.
|
|
• |
the knowledge, skills, expertise and accomplishments of the relevant office holder;
|
|
• |
the office holder’s roles and responsibilities and prior compensation agreements
with him or her;
|
|
• |
the relationship between the terms offered and the average compensation of the other
employees of the company, including those employed through manpower companies;
|
|
• |
the impact of disparities in salary upon work relationships in the company;
|
|
• |
the possibility of reducing variable compensation at the discretion of the board of
directors;
|
|
• |
the possibility of setting a limit on the exercise value of non-cash variable equity-based
compensation; and
|
|
• |
as to severance compensation, the period of service of the office holder, the terms
of his or her compensation during such service period, the company’s performance during that period of service, the person’s
contribution towards the company’s achievement of its goals and the maximization of its profits, and the circumstances under which
the person is leaving the company.
|
|
• |
the link between variable compensation and long-term performance, which variable compensation
shall, other than office holder who report to the CEO, be primarily based on measurable criteria;
|
|
• |
the relationship between variable and fixed compensation, and the ceiling for the
value of variable compensation;
|
|
• |
the conditions under which an office holder would be required to repay compensation
paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated
in the company’s financial statements;
|
|
• |
the minimum holding or vesting period for variable, equity-based compensation; and
|
|
• |
maximum limits for severance compensation.
|
|
• |
recommending whether a compensation policy should continue in effect, if the then-current
policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation
policy must in any case occur every three years, other than following a company’s initial public offering, in which case such approval
must occur within 5 years of the initial public offering);
|
|
• |
recommending to the board of directors periodic updates to the compensation policy
and assessing implementation of the compensation policy;
|
|
• |
approving compensation terms of executive officers, directors and employees that require
approval of the compensation committee; |
|
• |
determining whether the compensation terms of a chief executive officer nominee, which
were determined pursuant to the compensation policy, will be exempt from approval of the shareholders because such approval would harm
the ability to engage with such nominee; and
|
|
• |
determining, subject to the approval of the board and under special circumstances,
whether to override a determination of the company’s shareholders regarding certain compensation related issues.
|
|
• |
the responsibilities set forth in the compensation policy;
|
|
• |
reviewing and approving the granting of options and other incentive awards to the
extent such authority is delegated by our board of directors; and
|
|
• |
reviewing, evaluating and making recommendations regarding the compensation and benefits
for our non-employee directors.
|
|
• |
overseeing and assisting our board
in reviewing and recommending nominees for election of directors; |
|
• |
assessing the performance of the
members of our board; and |
|
• |
establishing and maintaining effective
corporate governance policies and practices, including, but not limited to, developing and recommending to our board a set of corporate
governance guidelines applicable to our business. |
|
• |
overseeing the Company's scientific, technical, research and development
strategy, and the implementation thereof; and |
|
• |
advising our board of directors and management regarding program prioritization,
clinical development strategy, regulatory strategy and interactions, and related matters. |
|
• |
a person (or a relative of a person) who holds 5% or more of the company’s outstanding
shares or voting rights;
|
|
• |
a person (or a relative of a person) who has the power to appoint a director or the
general manager of the company (i.e., the chief executive officer);
|
|
• |
an office holder (including a director) of the company (or a relative thereof); or
|
|
• |
a member of the company’s independent accounting firm, or anyone on its behalf.
|
|
• |
information on the advisability of a given action brought for his or her approval
or performed by virtue of his or her position; and
|
|
• |
all other important information pertaining to any such action.
|
|
• |
refrain from any conflict of interest between the performance of his or her duties
to the company and his or her other duties or personal affairs;
|
|
• |
refrain from any activity that is competitive with the business of the company;
|
|
• |
refrain from exploiting any business opportunity of the company to receive a personal
gain for himself or herself or others; and |
|
• |
disclose to the company any information or documents relating to the company’s
affairs which the office holder received as a result of his or her position as an office holder.
|
|
• |
a transaction other than in the ordinary course of business;
|
|
• |
a transaction that is not on market terms; or
|
|
• |
a transaction that may have a material impact on a company’s profitability,
assets or liabilities.
|
|
• |
at least a majority of the shares held by all shareholders who do not have a personal
interest in the transaction and who are present and voting at the meeting approves the transaction, excluding abstentions; or
|
|
• |
the shares voted against the transaction by shareholders who have no personal interest
in the transaction and who are present and voting at the meeting do not exceed 2% of the voting rights in the company.
|
|
• |
an amendment to the company’s articles of association; |
|
• |
an increase of the company’s authorized share capital;
|
|
• |
a merger; or
|
|
• |
the approval of related party transactions and acts of office holders that require
shareholder approval.
|
|
• |
financial liability imposed on him or her in favor of another person pursuant to a
judgment, including a settlement or arbitrator’s award approved by a court. However, if an undertaking to indemnify an office holder
with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the
board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount
or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail
the abovementioned foreseen events and amount or criteria;
|
|
• |
reasonable litigation expenses, including attorneys’ fees, incurred by the office
holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation
or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding, and
(ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation
or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal
intent; and (2) in connection with a monetary sanction; and
|
|
• |
reasonable litigation expenses, including attorneys’ fees, incurred by the office
holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection
with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require
proof of criminal intent. |
|
• |
a breach of the duty of loyalty to the company, provided that the office holder acted
in good faith and had a reasonable basis to believe that the act would not harm the company;
|
|
• |
a breach of duty of care to the company or to a third party, to the extent such a
breach arises out of the negligent conduct of the office holder; and
|
|
• |
a financial liability imposed on the office holder in favor of a third party.
|
|
• |
a breach of the duty of loyalty, except for indemnification and insurance for a breach
of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that
the act would not harm the company; |
|
• |
a breach of duty of care committed intentionally or recklessly, excluding a breach
arising out of the negligent conduct of the office holder;
|
|
• |
an act or omission committed with intent to derive illegal personal benefit; or
|
|
• |
a fine or forfeit levied against the office holder.
|
|
D. |
Employees |
|
E. |
Share Ownership |
|
A. |
Major Shareholders |
|
• |
each person or entity known by us to own beneficially more than 5% of our outstanding shares;
|
|
• |
each of our directors and executive officers individually; and
|
|
• |
all of our executive officers and directors as a group.
|
Name of Beneficial Owner |
Number of Shares Beneficially Held
|
Percentage of Class
|
||||||
Directors and Executive Officers |
||||||||
Nacchum (Homi) Shamir |
* |
* |
||||||
Ofer Gonen |
* |
* |
||||||
Assaf Segal |
* |
* |
||||||
Vickie R. Driver |
* |
* |
||||||
Nissim Mashiach |
* |
* |
||||||
Sharon Kochan |
* |
* |
||||||
David Fox |
* |
* |
||||||
Stephen T. Wills |
* |
* |
||||||
Sharon Malka |
96,127 |
1.01 |
% | |||||
Boaz Gur-Lavie |
* |
* |
||||||
Ety Klinger |
* |
* |
||||||
Yaron Meyer |
* |
* |
||||||
All executive officers and directors as a group (13 persons)( 1) |
309,285 |
3.30 |
% | |||||
Principal Shareholders (who are not Directors or Executive Officers)
|
||||||||
Clal Biotechnology Industries Ltd.(2) |
1,497,414 |
15.80 |
% | |||||
Point72 Associates, LLC |
821,500 |
8.70 |
% |
* |
Less than 1%. |
(1) |
Shares beneficially owned consist of 1,884,067 ordinary shares held directly or indirectly
by such executive officers and directors and 268,394 ordinary shares issuable upon exercise of outstanding options that are currently
exercisable or exercisable within 60 days of March 15, 2023. |
(2) |
Shares beneficially owned consist of: 1,172,710 ordinary shares held by Clal Life
Sciences, LP, whose managing partner is Clal Application Center Ltd., a wholly-owned subsidiary of CBI; (ii) 308,811 ordinary shares held
by CBI and (iii) 15,893 ordinary shares issuable upon exercise of outstanding options held directly by CBI that are currently exercisable
or exercisable within 60 days of March 15, 2023. As reported on a Schedule 13D/A filed on February 13, 2023 by Access Industries Holdings
LLC, Access Industries Holdings LLC indirectly owns 100% of the outstanding shares of Clal Industries Ltd., which owns 47.17% of the outstanding
shares of CBI. The address of Clal Industries Ltd. is the Triangular Tower, 3 Azrieli Center, Tel Aviv 67023, Israel and the address of
Access Industries Holdings LLC is c/o Access Industries Inc., 40 West 57th Street, New York, New York 10019, United States |
(3) |
As reported on a Schedule 13G filed on February 8, 2023, shares beneficially
owned consist of: 821,500 ordinary shares held by Point72 Associates, LLC which are controlled by Point72 Asset Management, L.P. pursuant
to an investment management agreement. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Steven
Cohen, as manager, controls each of Point72 Asset Management and Point72 Capital Advisors Inc. and their business address is 72 Cummings
Point Road, Stamford, CT 06902. |
|
B. |
Related Party Transactions |
C. |
Interests of Experts and Counsel |
Item 8. |
FINANCIAL INFORMATION |
|
A. |
Consolidated Statements and Other Financial Information |
|
B. |
Significant Changes |
Item 9. |
THE OFFER AND LISTING |
|
A. |
Listing Details |
B. |
Plan of Distribution |
|
C. |
Markets |
|
D. |
Selling Shareholders |
|
E. |
Dilution |
|
F. |
Expenses of the Issue |
Item 10. |
ADDITIONAL INFORMATION |
|
A. |
Share Capital |
|
B. |
Articles of Association |
C. |
Material Contracts |
|
D. |
Exchange Controls |
|
E. |
Taxation |
|
• |
banks, financial institutions or insurance companies;
|
|
• |
real estate investment trusts, regulated investment companies or grantor trusts;
|
|
• |
dealers or traders in securities, commodities or currencies;
|
|
• |
tax‑exempt entities or organizations, including an “individual retirement
account” or “Roth IRA” as defined in Section 408 or 408A of the Code, respectively;
|
|
• |
certain former citizens or long‑term residents of the United States;
|
|
• |
persons that received our shares as compensation for the performance of services;
|
|
• |
persons that holds our shares as part of a “hedging,” “integrated”
or “conversion” transaction or as a position in a “straddle” for U.S. federal income tax purposes;
|
|
• |
partnerships (including entities classified as partnerships for U.S. federal income
tax purposes) or other pass‑through entities, or holders that will hold our shares through such an entity;
|
|
• |
S corporations;
|
|
• |
holders that acquired ordinary shares as a result of holding or owning our preferred
shares;
|
|
• |
U.S. Holders (as defined below) whose “functional currency” is not the
U.S. dollar;
|
|
• |
persons that are residents of ordinarily resident in or have a permanent establishment
in a jurisdiction outside the United States; or
|
|
• |
holders that own directly, indirectly or through attribution 10.0% or more of the
voting power or value of our shares.
|
|
• |
an individual who is a citizen or individual resident of the United States;
|
|
• |
a corporation, or other entity taxable as a corporation for U.S. federal income tax
purposes, created or organized in or under the laws of the United States, any state thereof, or the District of Columbia;
|
|
• |
an estate, the income of which is subject to U.S. federal income taxation regardless
of its source; or
|
|
• |
a trust that (1) is subject to the primary supervision of a U.S. Court and one or
more U.S. persons that have the authority to control all substantial decisions of the trust or (2) has a valid election in effect under
applicable Treasury regulations to be treated as a U.S. person.
|
|
• |
such gain is effectively connected with your conduct of a trade or business in the
United States (or, if required by an applicable income tax treaty, the gain is attributable to a permanent establishment or fixed base
that such holder maintains in the United States); or
|
|
• |
you are an individual and have been present in the United States for 183 days or more
in the taxable year of such sale or exchange and certain other conditions are met.
|
|
• |
at least 75% of its gross income is “passive income”; or
|
|
• |
at least 50% of the average quarterly value of its total gross assets (which may be
determined in part by the market value of our ordinary shares, which is subject to change) is attributable to assets that produce “passive
income” or are held for the production of passive income.
|
|
Appreciation (Devaluation) of
|
|||||||
Period |
Shekel against the U.S. dollar
(%) |
Euro
against the U.S. dollar (%) |
||||||
|
||||||||
2020 |
7.0
|
8.0
|
||||||
2021 |
3.3
|
7.7 |
| |||||
2022 |
(13.2 |
) |
5.8 |
|
|
2021
|
2022
|
||||||
Audit Fees |
$ |
75,000 |
$ |
— | ||||
Audit‑Related Fees |
—
|
—
|
||||||
Tax Fees |
—
|
— |
||||||
Total
|
$ |
75,000 |
$ |
— |
|
2021
|
2022
|
||||||
Audit Fees |
$ |
170,000 |
$ |
270,000 |
||||
Audit‑Related Fees |
—
|
—
|
||||||
Tax Fees |
15,000
|
28,549 |
||||||
Total
|
$ |
185,000 |
$ |
298,549 |
|
• |
Quorum. As permitted under the Israeli Companies
Law pursuant to our articles of association, the quorum required for an ordinary meeting of shareholders will consist of at least two
shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least
25% of the voting power of our shares (and in an adjourned meeting, with some exceptions, at least two shareholders), instead of 33 1/3%
of the issued share capital required under the Nasdaq Stock Market listing rules. |
|
• |
Shareholder approval. We do not intend
to follow Nasdaq Stock Market rules which require shareholder approval in order to enter into any transaction, other than a public offering,
involving the sale, issuance or potential issuance by the Company of ordinary shares (or securities convertible into or exercisable for
ordinary shares) equal to 20% or more of the outstanding share capital of the Company or 20% or more of the voting power outstanding before
the issuance for less than the greater of book or market value of the ordinary shares. We will follow Israeli law with respect to any
requirement to obtain shareholder approval in connection with any private placements of equity securities. |
Exhibit No. |
Description |
4.19 |
|
4.20 |
|
4.21 |
|
4.22
|
|
101.INS |
Inline XBRL Instance Document |
|
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
|
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF |
Inline XBRL Taxonomy Definition Linkbase Document |
|
|
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
104 |
Cover Page Interactive Data File (the cover page iXBRL tags are embedded within the
Inline XBRL document) |
† |
Portions of this exhibit have been omitted pursuant to Instruction 4(a) to Exhibits
to Form 20-F because they are both (i) not material and (ii) the type that the Registrant treats as private or confidential.
|
(1)
|
Previously filed with the SEC on March 3, 2014
pursuant to the Registrant’s registration statement on Form F‑1 (File No. 333‑193856) and incorporated by reference
herein.
|
(2) |
Previously furnished to the SEC on May 5, 2021 as Appendix B to the Registrant’s
proxy statement for its 2021 annual general meeting of shareholders held on June 15, 2021, attached as Exhibit 99.1 to the Registrant’s
report of foreign private issuer on Form 6‑K (File No. 001‑36349) and incorporated by reference herein.
|
(3) |
Previously filed with the SEC on February 10, 2014 pursuant to the Registrant’s
registration statement on Form F‑1 (File No. 333‑193856) and incorporated by reference herein.
|
(4) |
Previously filed with the SEC on February 25, 2020 pursuant to the Registrant’s
annual report on Form 20-F for the year ended December 31, 2019 (File No. 001-36349) and incorporated by reference herein.
|
(5) |
Previously furnished to the SEC on August 14, 2019 as Appendix A to the Registrant’s
proxy statement for its extraordinary general meeting of shareholders held on September 23, 2019, attached as Exhibit 99.1 to the Registrant’s
report of foreign private issuer on Form 6‑K (File No. 001‑36349) and incorporated by reference herein.
|
(6) |
Previously filed with the SEC on February 25, 2021 pursuant to the Registrant’s
annual report on Form 20-F for the year ended December 31, 2020 (File No. 001-36349) and incorporated by reference herein.
|
(7) |
Previously filed with the SEC on January 25, 2016 as Exhibit 4.14 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2015 (File No. 001‑36349) and incorporated by reference herein.
|
(8) |
Previously filed with the SEC on February 21, 2017 as Exhibit 4.15 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2016 (File No. 001‑36349) and incorporated by reference herein.
|
(9) |
Previously filed with the SEC on March 19, 2018 as Exhibit 4.16 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2017 (File No. 001‑36349) and incorporated by reference herein.
|
(10) |
Previously filed with the SEC on March 25, 2019 as Exhibit 4.17 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2018 (File No. 001‑36349) and incorporated by reference herein.
|
(11) |
Previously filed with the SEC on March 19, 2018 as Exhibit 4.17 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2017 (File No. 001‑36349) and incorporated by reference herein.
|
(12) |
Previously filed with the SEC on March 25, 2019 as Exhibit 4.20 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2018 (File No. 001‑36349) and incorporated by reference herein.
|
(13)
|
Previously filed with the SEC on March 25, 2019 as Exhibit 4.21 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2018 (File No. 001‑36349) and incorporated by reference herein.
|
(14) |
Previously filed with the SEC by Vericel Corporation on August 6, 2019 as Exhibit
10.9 to its quarterly report on Form 10-Q for the quarter ended June 30, 2019 (File No. 001‑35280) and incorporated by reference
herein.
|
(15) |
Previously filed with the SEC by Vericel Corporation on August 6, 2019 as Exhibit
10.10 to its quarterly report on Form 10-Q for the quarter ended June 30, 2019 (File No. 001‑35280) and incorporated by reference
herein.
|
(16) |
Previously furnished to the SEC on June 9, 2022 as Appendix A to the Registrant’s
proxy statement for its 2022 annual general meeting of shareholders held on July 19, 2022, attached as Exhibit 99.1 to the Registrant’s
report of foreign private issuer on Form 6‑K (File No. 001‑36349) and incorporated by reference herein.
|
(17) |
Previously filed with the SEC on March 17, 2022 as Exhibit 4.11.7 to the Registrant’s
annual report on Form 20‑F for the year ended December 31, 2021 (File No. 001‑36349) and incorporated by reference herein.
|
(18) |
Previously furnished to the SEC
on September 26, 2022 as Exhibit 4.1 to the Registrant’s report of foreign private issuer on Form 6‑K (File No. 001‑36349)
and incorporated by reference herein.
|
(19) |
Previously furnished to the SEC
on September 26, 2022 as Exhibit 4.2 to the Registrant’s report of foreign private issuer on Form 6‑K (File No. 001‑36349)
and incorporated by reference herein.
|
(20) |
Previously furnished to the SEC
on September 26, 2022 as Exhibit 4.4 to the Registrant’s report of foreign private issuer on Form 6‑K (File No. 001‑36349)
and incorporated by reference herein. |
(21) |
Previously furnished to the SEC
on September 26, 2022 as Exhibit 10.3 to the Registrant’s report of foreign private issuer on Form 6‑K (File No. 001‑36349)
and incorporated by reference herein. |
|
MediWound Ltd. |
|
|
|
|
Date: March 16, 2023 |
By: /s/ Boaz Gur-Lavie |
|
|
Boaz Gur-Lavie |
|
|
Chief Financial Officer |
|
Page
|
|
|
|
(Firm Name: KPMG (Somekh Chaikin) / PCAOB ID No. |
F-2 – F-5 |
(Firm Name: KOST FORER GABBAY & KASIERER / PCAOB ID No. 1281) |
|
F-6
|
|
F -7
|
|
F-8
|
|
F-9 - F-10 |
|
F-11 - F-50 |
Kost Forer Gabbay & Kasierer
144 Menachem Begin Rd.
Tel-Aviv 6492102, Israel
|
Tel: +972-3-6232525
Fax: +972-3-5622555
ey.com
|
Description of the matter
|
As more fully described in Note 16b to the consolidated financial statements, under the Research and Development Lawthe Company undertook to pay royalties of 3% on the revenues derived from sales of products or services developed in whole or in part using IIA grants, up to the amount of total grants received, plus LIBOR interest. The liability to the IIA is measured at amortized cost using the effective interest method and amounted as of December 31, 2020 to $7,529 thousands.
Auditing the Company's IIA contingent liability involved a high degree of subjectivity as it is based on assumptions about future revenues forecast, such as long-term demand for the Company’s products and licenses and revenue growth rates. These significant assumptions are forward looking and could be affected by future economic and market conditions.
|
How we addressed the matter in our audit
|
Our substantive audit procedures included, among others, evaluating the significant assumptions and operating data used. For example, we analyzed the reasonableness of significant assumptions used to estimate future revenues based on historical trends, we did look back analyses, we obtained support to evaluate the accuracy of the data used in management's calculation and performed some independent recalculations.
|
|
/s/ KOST FORER GABBAY & KASIERER |
Tel-Aviv, Israel
|
KOST FORER GABBAY & KASIERER
|
February 25, 2021
|
A Member of Ernst & Young Global
|
As of December 31
|
|||||||||||
Note
|
2022
|
2021
|
|||||||||
Cash and cash equivalents
|
4
|
|
|
||||||||
Trade receivables
|
5
|
|
|
||||||||
Inventories
|
6
|
|
|
||||||||
Other receivables
|
7, 24
|
|
|
||||||||
Total current assets
|
|
|
|||||||||
Other receivables
|
8
|
|
|
||||||||
Property, plant and equipment, net
|
9
|
|
|
||||||||
Right-of-use assets, net
|
10
|
|
|
||||||||
Intangible assets, net
|
11
|
|
|
||||||||
Total non-current assets
|
|
|
|||||||||
Total assets
|
|
|
|||||||||
Current maturities of long-term liabilities
|
|
|
|||||||||
Trade payables and accrued expenses
|
|
|
|||||||||
Other payables
|
12, 24
|
|
|
||||||||
Total current liabilities
|
|
|
|||||||||
Deferred revenues
|
|
|
|||||||||
Warrants, net
|
18c
|
|
|
|
|||||||
Liabilities in respect of IIA grants
|
13, 16b
|
|
|
|
|||||||
Liabilities in respect of TEVA
|
16c
|
|
|
|
|||||||
Lease liabilities
|
10
|
|
|
||||||||
Severance pay liability, net
|
15
|
|
|
||||||||
Total non-current liabilities
|
|
|
|||||||||
Total liabilities
|
|
|
|||||||||
Shareholders' equity:
|
18
|
||||||||||
Ordinary shares of NIS
|
|||||||||||
Authorized * :
|
|
|
|||||||||
Share premium
|
|
|
|||||||||
Foreign currency translation reserve
|
(
|
)
|
(
|
)
|
|||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
|||||||
Total equity (deficit)
|
|
(
|
)
|
||||||||
Total liabilities and equity
|
|
|
MEDIWOUND LTD. AND ITS SUBSIDIARIES
Year Ended December 31
|
|||||||||||||
Note
|
2022
|
2021
|
2020
|
||||||||||
Revenues from sale of products
|
|
|
|
||||||||||
Revenues from development services
|
|
|
|
||||||||||
Revenues from license agreements
|
|
|
|
||||||||||
Total revenues
|
22a
|
|
|
|
|||||||||
Cost of revenues from sale of products
|
|
|
|
||||||||||
Cost of revenues from development services
|
|
|
|
||||||||||
Cost of revenues from license agreements
|
|
|
|
||||||||||
Total cost of revenues
|
22b
|
|
|
|
|||||||||
Gross profit
|
|
|
|
||||||||||
Research and development
|
22c
|
|
|
|
|||||||||
Selling and marketing
|
22d
|
|
|
|
|||||||||
General and administrative
|
22e
|
|
|
|
|||||||||
Other expenses
|
22f
|
|
|
|
|||||||||
Total operating expenses
|
|
|
|
||||||||||
Operating loss
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Financial income
|
|
|
|
||||||||||
Financial expense
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Financing expenses, net
|
22g
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Loss before taxes on income
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Taxes on income
|
(
|
)
|
(
|
)
|
|
||||||||
Loss from continuing operations
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Profit from discontinued operations
|
16c,21
|
|
|
|
|||||||||
Net loss for the year
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Other comprehensive income (loss):
|
|||||||||||||
Foreign currency translation adjustments
|
|
|
(
|
)
|
|||||||||
Total comprehensive loss
|
(
|
)
|
(
|
)
|
(
|
)
|
|||||||
Loss per share data
|
23,18
|
||||||||||||
Total basic and diluted net loss per share - USD
|
(
|
)
|
*(
|
)
|
*(
|
)
|
|||||||
Number of shares used in calculating basic loss per share
|
|
*
|
*
|
MEDIWOUND LTD. AND ITS SUBSIDIARIES
Share capital
|
Share premium
|
Foreign currency translation reserve
|
Accumulated
deficit
|
Total
equity (deficit)
|
||||||||||||||||
Balance as of January 1, 2022
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||
Net loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Other comprehensive income
|
|
|
|
|
|
|||||||||||||||
Total comprehensive loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Exercise of options
|
(
|
)
|
(
|
)
|
|
|
(
|
)
|
||||||||||||
Issuance of ordinary shares, net of issuance expenses (see note 18c)
|
|
|
|
|
|
|||||||||||||||
Exercise of pre-funded warrants (see note 18c)
|
|
|
|
|
|
|||||||||||||||
Share-based compensation
|
|
|
|
|
|
|||||||||||||||
Balance as of December 31, 2022
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Balance as of January 1, 2021
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Net loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Other comprehensive income
|
|
|
|
|
|
|||||||||||||||
Total comprehensive loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Exercise of options
|
(
|
)
|
|
|
|
|
||||||||||||||
Share-based compensation
|
|
|
|
|
|
|||||||||||||||
Balance as of December 31, 2021
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||
Balance as of January 1, 2020
|
|
|
(
|
)
|
(
|
)
|
|
|||||||||||||
Net loss
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||
Other comprehensive loss
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Total comprehensive loss
|
|
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||||||||
Exercise of options
|
(
|
)
|
(
|
)
|
-(
|
) |
|
(
|
)
|
|||||||||||
Share-based compensation
|
|
|
|
|
|
|||||||||||||||
Balance as of December 31, 2020
|
|
|
(
|
)
|
(
|
)
|
|
MEDIWOUND LTD. AND ITS SUBSIDIARIES
Year ended December 31,
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Cash flows from operating activities:
|
||||||||||||
Loss for the year
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Adjustments to reconcile net loss to net cash used in continuing operating activities:
|
||||||||||||
Adjustments to profit and loss items:
|
||||||||||||
Profit from discontinued operation
|
|
|
(
|
)
|
||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Share-based compensation
|
|
|
|
|||||||||
Revaluation of warrants accounted at fair value
|
|
|
|
|||||||||
Issuance expenses of warrants through profit and loss
|
|
|
|
|||||||||
Revaluation of liabilities in respect of IIA grants
|
(
|
)
|
|
|
||||||||
Revaluation of liabilities in respect of TEVA
|
|
|
(
|
)
|
||||||||
Revaluation of lease liabilities
|
(
|
)
|
|
|
||||||||
Increase in severance pay liability, net
|
|
|
|
|||||||||
Net financing income
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Un-realized foreign currency loss (gain)
|
|
(
|
)
|
(
|
)
|
|||||||
|
|
|
||||||||||
Changes in asset and liability items:
|
||||||||||||
Decrease (increase) in trade receivables
|
(
|
)
|
|
|
||||||||
Decrease (increase) in inventories
|
(
|
)
|
|
|
||||||||
Decrease (increase) in other receivables
|
|
(
|
)
|
(
|
)
|
|||||||
Increase (decrease) in trade payables and accrued expenses
|
|
|
(
|
)
|
||||||||
Increase (decrease) in other payables and deferred revenues
|
|
(
|
)
|
(
|
)
|
|||||||
(
|
)
|
|
(
|
)
|
||||||||
Net cash used in continuing operating activities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash used in discontinued operating activities
|
|
|
(
|
)
|
||||||||
Net cash used in operating activities
|
(
|
)
|
(
|
)
|
(
|
)
|
Year ended December 31,
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Cash flows from investing activities:
|
||||||||||||
Purchase of property and equipment
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Interest received
|
|
|
|
|||||||||
Proceeds from short term bank deposits, net
|
|
|
|
|||||||||
Net cash (used in) provided by investing activities
|
(
|
)
|
|
|
||||||||
Cash flows from financing activities:
|
||||||||||||
Repayment of leases liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from exercise of options
|
(
|
)
|
|
(
|
)
|
|||||||
Proceeds from exercise of pre-funded warrants
|
|
|
|
|||||||||
Proceeds from issuance of shares and warrants, net
|
|
|
|
|||||||||
Repayment of IIA grants, net
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Repayment of liabilities in respect of TEVA
|
(
|
)
|
|
|
||||||||
Net cash provided by (used in) continuing financing activities
|
|
(
|
)
|
(
|
)
|
|||||||
Exchange rate differences on cash and cash equivalent balances
|
(
|
)
|
|
|
||||||||
Increase (decrease) in cash and cash equivalents from continuing activities
|
|
(
|
)
|
|
||||||||
Decrease in cash and cash equivalents from discontinued activities
|
|
|
(
|
)
|
||||||||
Balance of cash and cash equivalents at the beginning of the year
|
|
|
|
|||||||||
Balance of cash and cash equivalents at the end of the year
|
|
|
|
|||||||||
Supplement disclosure of Non-cash transactions:
|
||||||||||||
ROU asset, net recognized with corresponding lease liability
|
|
|
|
MEDIWOUND LTD. AND ITS SUBSIDIARIES
Note 1: |
General
|
a. |
Description of the Company and its operations:
|
• |
The Company sell NexoBrid to burn centers in the European Union, United Kingdom and Israel, primarily through its commercial organizations.
|
• |
The Company have established local distribution channels in multiple international markets, focusing on Asia Pacific, EMEA, CEE and LATAM, which local distributors are also responsible for obtaining local marketing authorization within the relevant territories.
|
• |
In the United States, the Company entered into exclusive license and supply agreements with Vericel Corporation (“Vericel”) to commercialize NexoBrid in North America upon FDA approval.
|
Notes to the Consolidated Financial Statements
Note 1: |
General (Cont.)
|
b. |
The Company's securities are listed for trading on NASDAQ since March 2014.
|
c. |
The Company has three wholly owned subsidiaries: MediWound Germany GmbH, acting as Europe (“EU”) marketing authorization holder and EU sales and marketing arm, and MediWound UK Limited and MediWound US, Inc. which are currently inactive companies.
|
d. |
The Company awarded two contracts with the U.S. Biomedical Advanced Research and Development Authority ("BARDA") valued at up to $
|
e. |
On February 17, 2022 the Company engaged with the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), for a $
|
a. |
Statement of compliance with International Financial Reporting Standards
|
Notes to the Consolidated Financial Statements
b. |
Functional currency, reporting currency and foreign currency:
|
1. |
Functional currency and reporting currency:
|
2. |
Transactions, assets and liabilities in foreign currency:
|
Notes to the Consolidated Financial Statements
c. |
Use of estimates and judgments
|
• |
Determining the fair value of share based compensation to employees and directors:
|
• |
Liabilities in respect to IIA grants:
|
•
|
Fair value estimations of warrants
|
Note 3: |
Significant Accounting Policies
|
a. |
Basis of consolidation:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
b. |
Cash equivalents:
|
c. |
Short-term bank deposits:
|
d. |
Inventories:
|
Raw materials
|
-
|
At cost of purchase using the first-in, first-out method.
|
Finished goods
|
-
|
On the basis of average standard costs (which approximates actual cost on a weighted average basis) including materials, labor and other direct and indirect manufacturing costs based on practical capacity.
|
e. |
Property, plant and equipment, net:
|
%
|
||
Office furniture
|
|
|
Manufacturing machinery and lab equipment
|
|
|
Computers
|
|
|
Leasehold improvements
|
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
f. |
Intangible assets, net:
|
h. |
Leases:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
Years
|
|
Motor vehicles
|
|
Buildings and equipment
|
|
• |
Variable lease payments that depend on an index:
|
• |
Lease extension and termination options:
|
• |
Lease modifications:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
i. |
Revenues recognition:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
j. |
Research and development expenses:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
k. |
Impairment of non-financial assets:
|
l. |
Financial instruments:
|
1. |
Financial assets:
|
- |
The Company's business model for managing financial assets; and
|
- |
The contractual cash flow terms of the financial asset.
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
2. |
Financial liabilities:
|
a) |
Financial liabilities measured at amortized cost:
|
b) |
Financial liabilities measured at fair value through profit or loss:
|
3. |
Fair value:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
4.
|
Classification of financial instruments by fair value hierarchy:
|
Level 1
|
-
|
quoted prices (unadjusted) in active markets for identical assets or liabilities.
|
Level 2
|
-
|
inputs other than quoted prices included within level 1 that are observable either directly or indirectly.
|
Level 3
|
-
|
inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
|
5. |
Offsetting financial instruments:
|
m. |
Warrants:
|
n. |
Provisions:
|
o. |
Short-term employee benefits and severance pay liability, net:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
p. |
Share-based compensation:
|
q. |
Discontinued operation:
|
Notes to the Consolidated Financial Statements
Note 3: |
Significant Accounting Policies (Cont.)
|
r. |
Profit / Loss per share:
|
s. |
New standards, amendments to standards and interpretations not yet adopted:
|
Notes to the Consolidated Financial Statements
Note 4: |
Cash and Cash Equivalents
|
December 31
|
||||||||
2022
|
2021
|
|||||||
Balance in USD
|
|
|
||||||
Balance in other currencies
|
|
|
||||||
|
|
Note 5: |
Trade Receivables
|
December 31,
|
||||||||
2022
|
2021
|
|||||||
Vericel (Note 17b)
|
|
|
||||||
BARDA (Note 17a)
|
|
|
||||||
Other trade receivables
|
|
|
||||||
Less provision for impairment
|
(
|
)
|
(
|
)
|
||||
|
|
Note 6: Inventories
December 31,
|
||||||||
2022
|
2021
|
|||||||
Raw materials
|
|
|
||||||
Finished goods
|
|
|
||||||
|
|
Note 7: |
Other Receivables- Short Term
|
December 31,
|
||||||||
2022
|
2021
|
|||||||
Government authorities
|
|
|
||||||
Contract asset related to BARDA
|
|
|
||||||
Prepaid expenses and other
|
|
|
||||||
|
|
Note 8: |
Other Receivables- Long Term
|
December 31,
|
||||||||
2022
|
2021
|
|||||||
Income receivables
|
|
|
||||||
Restricted bank deposits (1)
|
|
|
||||||
|
|
(1) |
|
Notes to the Consolidated Financial Statements
Note 9: Property, Plant And Equipment, Net
Cost
|
Office
furniture
|
Manufacturing
machinery
and lab
equipment
|
Computers
|
Leasehold
improvements
|
Total
|
|||||||||||||||
Balance as of January 1, 2022
|
|
|
|
|
|
|||||||||||||||
Additions
|
|
|
|
|
|
|||||||||||||||
Disposals
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Foreign currency translation
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||
Balance as of December 31, 2022
|
|
|
|
|
|
|||||||||||||||
Balance as of January 1, 2021
|
|
|
|
|
|
|||||||||||||||
Additions
|
|
|
|
|
|
|||||||||||||||
Disposals
|
(
|
)
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Foreign currency translation
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
||||||||||||
Balance as of December 31, 2021
|
|
|
|
|
|
|||||||||||||||
Accumulated Depreciation
|
||||||||||||||||||||
Balance as of January 1, 2022
|
|
|
|
|
|
|||||||||||||||
Additions
|
|
|
|
|
|
|||||||||||||||
Disposals
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||
Foreign currency translation
|
(
|
)
|
|
|
|
(
|
)
|
|||||||||||||
Balance as of December 31, 2022
|
|
|
|
|
|
|||||||||||||||
Balance as of January 1, 2021
|
|
|
|
|
|
|||||||||||||||
Additions
|
|
|
|
|
|
|||||||||||||||
Disposals
|
(
|
)
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Foreign currency translation
|
(
|
)
|
(
|
)
|
(
|
)
|
|
(
|
)
|
|||||||||||
Balance as of December 31, 2021
|
|
|
|
|
|
|||||||||||||||
Carrying amounts of all fixed asset items
|
December 31, 2022
|
|
|
|
|
|
|||||||||||||||
December 31, 2021
|
|
|
|
|
|
Notes to the Consolidated Financial Statements
Note 10: |
Leases
|
a. |
Lease Agreements:
|
b. |
Amounts recognized in profit or loss and in the statement of cash flows
|
Year ended December 31,
|
||||||||
2022
|
2021
|
|||||||
Interest expense on lease liabilities
|
|
|
||||||
Depreciation expenses relating to short-term leases
|
|
|
||||||
Cash outflow for leases
|
|
|
Notes to the Consolidated Financial Statements
c. |
Disclosures in respect of Right- of- Use assets:
|
Buildings
|
Motor
vehicles
|
Total
|
||||||||||
Cost
|
||||||||||||
Balance as of January 1, 2022
|
|
|
|
|||||||||
New leases
|
|
|
|
|||||||||
Adjustments for indexation
|
|
|
|
|||||||||
Disposals
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2022
|
|
|
|
|||||||||
Accumulated depreciation
|
||||||||||||
Balance as of January 1, 2022
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Disposals
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2022
|
|
|
|
|||||||||
Depreciated cost
|
||||||||||||
Balance as of December 31, 2022
|
|
|
|
Buildings
|
Motor
vehicles
|
Total
|
||||||||||
Cost
|
||||||||||||
Balance as of January 1, 2021
|
|
|
|
|||||||||
New leases
|
|
|
|
|||||||||
Adjustments for indexation
|
|
|
|
|||||||||
Disposals
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2021
|
|
|
|
|||||||||
Accumulated depreciation
|
||||||||||||
Balance as of January 1, 2021
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Disposals
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2021
|
|
|
|
|||||||||
Depreciated cost
|
||||||||||||
Balance as of December 31, 2021
|
|
|
|
Notes to the Consolidated Financial Statements
Note 10: |
Leases (Cont.)
|
d.
|
Disclosures of the Company's lease liabilities :
|
Buildings
|
Motor
vehicles
|
Total
|
||||||||||
Balance as of January 1, 2022
|
|
|
|
|||||||||
Repayment of leases liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Effect of changes in exchange rates
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
New finance lease obligation recognized
|
|
|
|
|||||||||
Adjustments for indexation
|
|
|
|
|||||||||
Financial expenses
|
|
|
|
|||||||||
Disposals-Termination of leases
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2022
|
|
|
|
|||||||||
Current maturities of long-term leases
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Lease liability Balance as of December 31, 2022
|
|
|
|
Buildings
|
Motor
vehicles
|
Total
|
||||||||||
Balance as of January 1, 2021
|
|
|
|
|||||||||
Repayment of leases liabilities
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Effect of changes in exchange rates
|
|
|
|
|||||||||
New finance lease obligation recognized
|
|
|
|
|||||||||
Adjustments for indexation
|
|
|
|
|||||||||
Financial expenses
|
|
|
|
|||||||||
Disposals-Termination of leases
|
|
(
|
)
|
(
|
)
|
|||||||
Balance as of December 31, 2021
|
|
|
|
|||||||||
Current maturities of long-term leases
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Lease liability Balance as of December 31, 2021
|
|
|
|
Note 11: Intangible Assets, Net
License and
Knowhow
|
||||||||
2022
|
2021
|
|||||||
Cost
|
||||||||
Balance as of January 1,
|
|
|
||||||
Additions
|
|
|
||||||
Balance as of December 31,
|
|
|
||||||
Accumulated Amortization
|
||||||||
Balance as of January 1,
|
|
|
||||||
Additions
|
|
|
||||||
Balance as of December 31,
|
|
|
||||||
Amortized cost
|
||||||||
Balance as of December 31,
|
|
|
Notes to the Consolidated Financial Statements
December 31,
|
||||||||
2022
|
2021
|
|||||||
Employees and payroll accruals
|
|
|
||||||
Liability in respect of TEVA (see Note 16c)
|
|
|
||||||
Related parties
|
|
|
||||||
Deferred revenues
|
|
|
||||||
Other
|
|
|
||||||
|
|
Note 13: Liabilities in Respect of IIA Grants
December 31
|
||||||||
2022
|
2021
|
|||||||
Balance as of January 1,
|
|
|
||||||
Royalties
|
(
|
)
|
(
|
)
|
||||
Amounts carried to Profit or Loss
|
(
|
)
|
|
|||||
Balance as of December 31,
|
|
|
||||||
Current maturities
|
(
|
)
|
(
|
)
|
||||
Long term liabilities in respect of IIA grants
|
|
|
Notes to the Consolidated Financial Statements
Note 14: |
Financial Instruments
|
a. |
Risk management:
|
1. |
Foreign currency risk
|
2. |
Sensitivity tests relating to changes in market factors:
|
December 31
|
||||||||
2022
|
2021
|
|||||||
Gain (loss) from change:
|
||||||||
5% increase in NIS and EURO exchange rate
|
$
|
|
$
|
|
||||
5% decrease in NIS and EURO exchange rate
|
$
|
(
|
)
|
$
|
(
|
)
|
Notes to the Consolidated Financial Statements
Note 14: |
Financial Instruments (Cont.)
|
3. |
Liquidity risk
|
December 31, 2022
|
||||||||||||||||
Carrying
|
12 months
|
|||||||||||||||
amount
|
or less
|
1-2 years
|
2-8 years
|
|||||||||||||
Non-derivative financial liabilities
|
||||||||||||||||
Current liabilities
|
||||||||||||||||
Current maturities of long-term liabilities
|
|
|
|
|
||||||||||||
Trade payables and accrued expenses
|
|
|
|
|
||||||||||||
Other payables
|
|
|
|
|
||||||||||||
Non-current liabilities
|
||||||||||||||||
Liabilities in respect of IIA grants
|
|
|
|
|
||||||||||||
Liabilities in respect of TEVA
|
|
|
|
|
||||||||||||
Lease liabilities
|
|
|
|
|
December 31, 2021
|
||||||||||||||||
Carrying
|
12 months
|
|||||||||||||||
amount
|
or less
|
1-2 years
|
2-8 years
|
|||||||||||||
Non-derivative financial liabilities
|
||||||||||||||||
Current liabilities
|
||||||||||||||||
Current maturities of long-term liabilities
|
|
|
|
|
||||||||||||
Trade payables and accrued expenses
|
|
|
|
|
||||||||||||
Other payables
|
|
|
|
|
||||||||||||
Non-current liabilities
|
||||||||||||||||
Liabilities in respect of IIA grants
|
|
|
|
|
||||||||||||
Liabilities in respect of TEVA
|
|
|
|
|
||||||||||||
Lease liabilities
|
|
|
|
|
Notes to the Consolidated Financial Statements
Note 14: |
Financial Instruments (Cont.)
|
b.
|
Fair value:
|
(1) |
Financial instruments measured at fair value for disclosure purposes only.
|
(2) |
Fair value hierarchy of financial instruments measured at fair value.
|
Note 15: |
Severance Pay Liabilty, Net
|
Notes to the Consolidated Financial Statements
Note 15: |
Severance Pay Liabilty, Net (Cont.)
|
Note 16: |
Liabilities and Commitments
|
a. |
In 2000, the Company signed an exclusive license agreement (as amended in 2007) with a third party with regard to its patents and intellectual property. Pursuant to the agreement, the Company received an exclusive license to use the third party’s patents and intellectual property, for the purpose of developing, manufacturing, marketing, and commercializing products for treatment of burns and other wounds.
|
b. |
Under the Research and Development Law, (the “R&D Law”) the Company undertook to pay royalties of
|
c. |
In December 2020, Teva has agreed to revise the Settlement Agreement from March 2019, which was comprised of past agreement for collaboration in the development, manufacturing and commercialization of solutions for the burn and chronic wound care markets, as well as the Company’s repurchase of shares from Teva. Under the new settlement the Company paid $
|
Notes to the Consolidated Financial Statements
Note 16: |
Liabilities and Commitments (Cont.)
|
Note 17: |
Materials Agreements
|
a. |
BARDA Contracts
|
b. |
Vericel Agreement:
|
Notes to the Consolidated Financial Statements
Note 17: |
Materials Agreememts (Cont.)
|
Note 18: |
Equity
|
a. |
Share capital:
|
December 31
|
||||||||
2022
|
2021
|
|||||||
Authorized number of shares
|
|
*
|
||||||
Issued and outstanding number of shares
|
|
*
|
b. |
Movement in share capital:
|
1. |
During 2020 and 2021 the Company issued additional
|
2. |
On November 28, 2022, at the Company’s extraordinary general meeting of shareholders, its shareholders approved:
|
(a) |
An increases of the Company’s authorized share capital from NIS
|
(b)
|
A reverse stock split, in a range of between 1-for-5 and 1-for-10, subject to the discretion of our board of directors to implement it within 12 months.
|
Notes to the Consolidated Financial Statements
Note 18: |
Equity (Cont.)
|
3. |
During 2022 the Company issued additional
|
c. |
Financial transactions:
|
1. |
On March 7, 2022, the Company completed a public offering in total of
|
2. |
On September 26, 2022, the Company completed a registered direct (the “RD”) offering in an aggregate amount of $
|
Notes to the Consolidated Financial Statements
Note 18: |
Equity (Cont.)
|
3. |
Concurrently, on October 6, 2022, the Company entered into a Private Issuance Purchase Equity agreement (the “PIPE”) with several purchasers, in connection with the offering of
|
4. |
Upon closing of the RD and PIPE Offerings, the Company also issued the placement agent up to
|
5. |
See also Note 25.1 regarding a public offering after the reporting date.
|
Notes to the Consolidated Financial Statements
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Cost of revenues
|
|
|
|
|||||||||
Research and development
|
|
|
|
|||||||||
Selling and marketing
|
|
|
|
|||||||||
General and administrative
|
|
|
|
|||||||||
Total share-based compensation
|
|
|
|
b. Share-based payment plan for employees and directors:
As of December 31, 2022,
Notes to the Consolidated Financial Statements
Note 19: Share‑Based Compensation (Cont.) |
c. Share options activity:
2022
|
2021*
|
2020*
|
||||||||||||||||||||||
Number of
options
|
Weighted
Average
Exercise price
|
Number of
options
|
Weighted
Average
Exercise price
|
Number of
options
|
Weighted
Average
Exercise price
|
|||||||||||||||||||
Outstanding Options at beginning of year
|
|
|
|
|
|
|
||||||||||||||||||
Options Granted
|
|
|
|
|
|
|
||||||||||||||||||
Options Exercised
|
(
|
)
|
|
(
|
) |
|
|
|
||||||||||||||||
Options Forfeited and/or expired
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
|
|||||||||||||||
Outstanding options and at end of year
|
|
|
|
|
|
|
||||||||||||||||||
Option's Exercisable at end of year
|
|
|
|
|
|
|
*Restated o reflect 1:7 reverse ratio of shares (See note 18b)
The following table summarizes information about share options outstanding:
Options outstanding as of
December 31, 2022
|
||||||||||||
Range of exercise prices ($ )
|
Number of
options
|
Weighted
Average
Remaining
contractual
life
|
Weighted
average
exercise
price
|
|||||||||
12.25-14.42 |
|
|
|
|||||||||
26.88-37.52 |
|
|
|
|||||||||
42.14-67.06 |
|
|
|
|||||||||
90.23-96.32 |
|
|||||||||||
Total
|
|
|
|
|
Options outstanding as of December31, 2021* |
|||||||||||
Range of exercise prices ($) |
Number of options |
Weighted Average Remaining contractual life |
Weighted average exercise price |
|||||||||
|
||||||||||||
12.25-37.52 |
|
|
|
|||||||||
42.14-67.06 |
|
|
|
|||||||||
90.23-96.32 |
|
|
|
|||||||||
Total |
|
|
|
Notes to the Consolidated Financial Statements
Note 19: Share‑Based Compensation (Cont.)
The following table summarizes information about RSU's outstanding:
RSU's
2022
|
RSU's
2021*
|
RSU's
2020*
|
||||||||||
Outstanding at beginning of year
|
|
|
|
|||||||||
Granted
|
|
|
|
|||||||||
Forfeited
|
(
|
) |
(
|
) |
|
|||||||
Vested
|
(
|
) |
(
|
)
|
(
|
)
|
||||||
Outstanding at the end of the period
|
|
|
|
*Restated o reflect 1:7 reverse ratio of shares (See note 18b)
1. |
On April 23, 2020, the Company's Board of Directors approved the grant of
|
2. | On March 4, 2021, the Company's Board of Directors approved the grant of: (a) |
|
3. |
Over the second quarter of 2022, the Company’s Board of Directors approved the grant of
The above-mentioned grant includes the grant of |
|
4. |
On July 19, 2022, the Company’s Shareholders General meeting approved the abovementioned grants (Note 3p, Note 19) to the directors and the CEO, the compensation terms of Mr. Ofer Gonen as the Company’s new Chief Executive Officer, which terms will be effective as of July 1, 2022 and the termination terms for the previous CEO. |
Notes to the Consolidated Financial Statements
Note 19: Share‑Based Compensation (Cont.)
5. | On August 18, 2022, the Company’s Shareholders General meeting approved the compensation terms and grant of |
d. The fair value of the Company's share options granted to employees and directors for the years ended December 31, 2020, 2021 and 2022 was estimated using the binomial option pricing models using the following assumptions:
December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Dividend yield (%)
|
|
|
|
|||||||||
Expected volatility of the share prices (%)
|
|
|
|
|||||||||
Risk-free interest rate (%)
|
|
|
|
|||||||||
Early exercise factor (%)
|
|
|
|
|||||||||
Weighted average share prices (Dollar)
|
|
|
|
Measurement inputs include the share price on the measurement date, the exercise price of the instrument, expected volatility (based on the weighted average volatility of the Company’s shares, over the expected term of the options), expected term of the options (based on general option holder behavior and expected share price), expected dividends, and the risk-free interest rate (based on government debentures).
Note 20: |
Income Tax
|
a. |
The Company operates in two main tax jurisdictions: Israel and Germany. As such, the Company is subject to the applicable tax rates in the jurisdictions in which it conducts its business.
|
b. |
Corporate tax rate in Israel:
|
c. |
Benefits under the Law for the Encouragement of Capital Investments:
|
Notes to the Consolidated Financial Statements
Note 20: |
Income Tax (Cont.)
|
d. |
The principal tax rates applicable to the subsidiary whose place of incorporation is outside of Israel is:
|
e. |
Final tax assessments:
|
f. |
Net operating carryforward losses for tax purposes and other temporary differences:
|
g. |
Deferred taxes:
|
h. |
Current taxes on income:
|
i. |
Theoretical tax:
|
Notes to the Consolidated Financial Statements
Note 21: Discontinued Operation
Note 22: |
Supplementary Information to the Statements of Comprehensive Profit or Loss
|
a.
|
Additional information on Revenues:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
USA ( see also Note 17a, 17b)
|
|
|
|
|||||||||
EU and other international markets
|
|
|
|
|||||||||
|
|
|
b.
|
Cost of Revenues:
|
1. |
Cost of Revenues from sale of products
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits (including share-based compensation)
|
|
|
|
|||||||||
Subcontractors
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Cost of materials
|
|
|
|
|||||||||
Other manufacturing expenses
|
|
|
|
|||||||||
Decrease (increase) in inventory of finished products
|
(
|
)
|
|
|
||||||||
|
|
|
Notes to the Consolidated Financial Statements
Note 22: |
Supplementary Information to the Statements of Comprehensive Profit or Loss (Cont.)
|
2. |
Cost of Revenues from development services
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits
|
|
|
|
|||||||||
Subcontractors
|
|
|
|
|||||||||
|
|
|
3. |
Cost of Revenues from license agreements
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits
|
|
|
|
|||||||||
Royalties payments
|
|
|
|
|||||||||
|
|
|
||||||||||
Total Cost of Revenues
|
|
|
|
c.
|
Research and development expenses, net of participations:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits (including share-based compensation)(1)
|
|
|
|
|||||||||
Subcontractors
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Cost of materials
|
|
|
|
|||||||||
Other research and development expenses
|
|
|
|
|||||||||
Total Research and development, net of participations
|
|
|
|
(1) |
The salary costs for the year ended December 31,2022 includes one time payment of $
|
Notes to the Consolidated Financial Statements
d.
|
Selling and marketing expenses:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits (including share based compensation)
|
|
|
|
|||||||||
Marketing and medical support
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Shipping and delivery
|
|
|
|
|||||||||
Registration and marketing license fees
|
|
|
|
|||||||||
|
|
|
e.
|
General and administrative expenses:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Salary and benefits (including share‑based compensation)
|
|
|
|
|||||||||
Professional fees
|
|
|
|
|||||||||
Depreciation and amortization
|
|
|
|
|||||||||
Other
|
|
|
|
|||||||||
|
|
|
f. |
Other expenses:
|
Notes to the Consolidated Financial Statements
Note 22: |
Supplementary Information to the Statements of Comprehensive Profit or Loss (Cont.)
|
g. |
Financial income and expense:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Financial income:
|
||||||||||||
Interest income
|
|
|
|
|||||||||
Revaluation of liabilities in respect of TEVA
|
|
|
|
|||||||||
Revaluation of liabilities in respect of IIA grants
|
|
|
|
|||||||||
Exchange differences, net
|
|
|
|
|||||||||
|
|
|
||||||||||
Financial expense:
|
||||||||||||
Interest in respect of IIA grants
|
|
|
|
|||||||||
Revaluation of liabilities in respect of IFRS16
|
|
|
|
|||||||||
Finance expenses in respect of deferred revenues
|
|
|
|
|||||||||
Revaluation of liabilities in respect of TEVA
|
|
|
|
|||||||||
Exchange differences, net
|
|
|
|
|||||||||
Revaluation of Warrants
|
|
|
|
|||||||||
Issuance expenses of warrants through profit and loss
|
|
|
|
|||||||||
Other
|
|
|
|
|||||||||
|
|
|
||||||||||
Financial expenses, net
|
(
|
)
|
(
|
)
|
(
|
)
|
a. |
Details of the number of shares and loss used in the computation of loss per share from continuing operations:
|
Year ended December 31
|
||||||||||||||||||||||
2022
|
2021*
|
2020*
|
||||||||||||||||||||
Weighted
average
number of shares
|
Loss
|
Weighted
average
number of shares
|
Loss
|
Weighted
average
number of shares
|
Loss
|
|||||||||||||||||
|
(
|
)
|
|
(
|
)
|
|
(
|
)
|
Notes to the Consolidated Financial Statements
b. |
Net profit (loss) per share :
|
Year ended December 31
|
||||||||||||
2022
|
2021*
|
|
2020*
|
|
||||||||
Basic and diluted loss per share:
|
(
|
)
|
(
|
)
|
(
|
)
|
Note 24: Balances and Transactions With Related Parties and Key Officers
a. |
Related parties consist of:
|
• |
Clal Biotechnologies Industries Ltd.- Related party.
|
• |
Directors of the Company.
|
1. |
Balances of related parties:
|
Other Payables
|
||||
Related Party:
|
||||
As of December 31, 2021
|
|
|||
As of December 31, 2022
|
|
|||
Directors:
|
||||
As of December 31, 2021
|
|
|||
As of December 31, 2022
|
|
2. |
Transactions with related parties:
|
Rental fee:
|
Year ended December 31
|
|||||||||||
2022
|
2021
|
2020
|
||||||||||
Related party
|
|
|
|
Professional fee *:
|
Year ended December 31
|
|||||||||||
2022
|
2021
|
2020
|
||||||||||
Directors
|
|
|
|
|||||||||
Related party
|
|
|
|
|||||||||
|
|
|
||||||||||
Number of Directors
|
*
|
|
|
* |
Not included share based compensation detailed in Note 19.
|
* |
During 2022 two members of the board of directors were replaced.
|
Notes to the Consolidated Financial Statements
Note 24: Balances and Transactions With Related Parties and Key Officers (Cont.)
b. |
Key Officers:
|
1. |
Balances of Key Officers of the Company
|
Other Payables
|
||||
Key Officers of the Company
|
||||
As of December 31, 2022
|
|
|||
As of December 31, 2021
|
|
• |
Represents the officer’s gross salary, bonuses and vacation provisions without share based compensation.
|
2. |
Compensation of Key Officers of the Company:
|
Year ended December 31
|
||||||||||||
2022
|
2021
|
2020
|
||||||||||
Short-term employee benefits (*)(**)
|
|
|
|
|||||||||
Share-based compensation
|
|
|
|
|||||||||
|
|
|
||||||||||
Number of officers
|
|
|
|
1. |
On February 7, 2023, the Company completed a registered direct offering. A total of
|
2. |
On February 15, 2023, the Company granted to employees, officers, board members, CEO and some consultants
|
1.1. |
In these Articles, unless the context requires another meaning the words in the first column of the following table shall have
the meanings set opposite them in the second column:
|
“Alternate Nominee”
|
as defined in Article 77.1;
|
“Articles”
|
these Articles of Association, as amended from time to time by a Resolution (as defined below);
|
“Auditors”
|
the auditors of the Company;
|
“Board of Directors”
|
all of the directors of the Company holding office pursuant to these Articles, including alternates, substitutes or proxies;
|
“Chief Executive Officer”
|
chief executive officer of the Company;
|
“Chairman of the Board of Directors”
|
as defined in Article 81;
|
“Companies Law”
|
the Israeli Companies Law, 5759-1999, as amended from time to time, including the regulations promulgated thereunder, or any other law which
may come in its stead, including all amendments made thereto;
|
“Company”
|
MediWound Ltd. or מדיוונד בע"מ;
|
“Committee of Directors”
|
as defined in Article 93;
|
“Compensation Committee”
|
as defined in the Companies Law;
|
“Deed of Transfer”
|
as defined in Article 44;
|
“Derivative Transaction”
|
as defined in Article 56;
|
“Effective Time”
|
the closing of the initial underwritten public offering of the Company’s Ordinary Shares, at which time these Articles shall first become
effective;
|
“Director(s)”
|
a member or members of the Board of Directors elected to hold office as director(s);
|
“External Directors”
|
as defined in the Companies Law;
|
“General Meetings”
|
all annual and extraordinary meetings of the Shareholders;
|
“Incapacitated Person”
|
as defined under the Israeli Legal Capacity and Guardianship Law, 5722-1962, as amended from time to time, including a minor who has not yet
attained the age of 18 years, a person unsound of mind and a bankrupt in respect of whom no rehabilitation has been granted;
|
“NIS”
|
New Israeli Shekels;
|
“Nominees”
|
as defined in Article 77.1;
|
“Ordinary Shares”
|
as defined in Article 6;
|
“Office”
|
the registered office of the Company at that time;
|
“Office Holder”
|
as defined in the Companies Law;
|
“Person”
|
includes an individual, corporation, company, cooperative society, partnership, trust of any kind or
any other body of persons, whether incorporated or otherwise;
|
“Proposal Request”
|
as defined in Article 56;
|
“Proposing Shareholder”
|
as defined in Article 56;
|
“Register”
|
the Register of Shareholders administered in accordance with the Companies Law;
|
“Resolution”
|
a resolution of Shareholders. Except as required under the Companies Law or these Articles, any Resolution shall be adopted by a majority of the voting power present and voting at the applicable
General Meeting, in person or by proxy;
|
“Rights”
|
as defined in Article 113.1;
|
“Shareholder(s)”
|
shall mean the shareholder(s) of the Company, at any given time;
|
“Special Fund”
|
as defined in Article 113.1;
|
“Transferor”
|
as defined in Article 44;
|
“Transferee”
|
as defined in Article 44;
|
“U.S. Rules”
|
the applicable rules of the NASDAQ Stock Market and the U.S. securities rules and regulations, as amended from time to time; and
|
“writing”
|
handwriting, typewriting, photography, telex, email or any other legible form of writing.
|
1.2. |
Subject to the provisions of this Article 1, in these Articles, unless the context necessitates another meaning, terms and
expressions which have been defined in the Companies Law shall have the meanings ascribed to them therein.
|
1.3. |
Words in the singular shall also include the plural, and vice versa. Words in the masculine shall include the feminine and vice
versa, and words which refer to persons shall also include corporations, and vice versa.
|
1.4. |
The captions to articles in these Articles are intended for the convenience of the reader only, and no use shall be made
thereof in the interpretation of these Articles.
|
2. |
The Company is a limited liability company and therefore each shareholder’s obligations for the Company’s obligations shall be limited to the payment of the nominal value of the shares held by such shareholder, subject to the provisions of the Companies Law.
|
3. |
The Company’s objectives are to conduct all types of business as are permitted by law. The Company may donate a
reasonable amount of money for any purpose that the Board of Directors finds appropriate, even if the donation is not for business considerations or for the purpose of achieving profits for the Company.
|
4. |
Any branch or type of business that the Company is authorized to engage in, either expressly or implied, may be commenced or engaged in by the Board of
Directors at all or any time as it deems fit. The Board of Directors shall be entitled to cease the conduct of any such branch or type of business, whether or not the actual conduct thereof has commenced at its
own discretion.
|
5. |
The registered office shall be at such place as is decided from time to time by the Board of Directors.
|
6. |
The share capital of the Company shall consist of NIS 900,000 divided into 12,857,143 Ordinary Shares, of a nominal value of NIS
0.07 each (the “Ordinary Shares”).
|
7.1. |
The Ordinary Shares in respect of which all calls have been fully paid shall confer on the holders thereof the right to attend
and to vote at General Meetings of the Company, both ordinary as well as extraordinary meetings.
|
7.2. |
The Ordinary Shares shall confer on a holder thereof the right to receive a dividend, to participate in a distribution of
bonus shares and to participate in the distribution of the assets of the Company upon its winding-up, pro rata to the nominal amount paid up on the shares or credited as paid up in respect thereof, and without reference to
any premium which may have been paid in respect thereof.
|
8.1. |
Subject to applicable law, if at any time the share capital of the Company is divided into different classes of shares
and unless the terms of issue of such class of shares otherwise stipulate, the rights attaching to any class of shares (including rights prescribed in the terms of issue of the shares)
may be altered, modified or canceled, by a Resolution passed at a separate General Meeting of the Shareholders of that class.
|
8.2. |
The provisions contained in these Articles with regard to General Meetings shall apply, mutatis mutandis as the case may be, to every General Meeting of the holders of each such class of the Company’s shares.
|
8.3. |
Unless otherwise provided by these Articles, the increase of an authorized class of shares, or the issuance of
additional shares thereof out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 8.30, to modify or abrogate the rights attached to previously issued shares of such
class or of any other class.
|
9. |
The unissued shares in the capital of the Company shall be under the control of the Board of Directors, which shall be entitled to allot or otherwise grant the
same to such Persons under such restrictions and conditions as it shall deem fit, whether for consideration or otherwise, and whether for consideration in cash or for consideration which is not in cash, above their nominal value or at a
discount, all on such conditions, in such manner and at such times as the Board of Directors shall deem fit, subject to the provisions of the Companies Law. The Board of Directors shall be entitled, inter
alia, to differentiate between Shareholders with regard to the amounts of calls in respect of the allotment of shares (to the extent that there are calls) and with regard to the time for payment thereof. The Board of Directors may
also issue options or warrants for the purchase of shares of the Company and prescribe the manner of the exercise of such options or warrants, including the time and price for such exercise and any other provision which is relevant to the
method for distributing the issued shares of the Company amongst the purchasers thereof.
|
10. |
The Board of Directors shall be entitled to prescribe the times for the issue of shares of the Company and the conditions therefore and any other matter which
may arise in connection with the issue thereof.
|
11. |
In every case of a rights offering the Board of Directors shall be entitled, in its discretion, to resolve any problems and difficulties arising or that are
likely to arise in regard to fractions of rights, and without prejudice to the generality of the foregoing, the Board of Directors shall be entitled to specify that no shares shall be allotted in respect of fractions of rights, or that
fractions of rights shall be sold and the (net) proceeds shall be paid to the persons entitled to the fractions of rights, or, in accordance with a decision by the Board of Directors, to the benefit of the Company.
|
11A. |
The Company may, subject to applicable law, issue redeemable shares and redeem the same. Shares issued by the Company may be redeemable upon terms and
conditions to be set forth in a written agreement between the Company and the holder of such shares.
|
12. |
The Company may, from time to time, by a Resolution, increase its share capital by way of the creation of new shares, whether or not all the existing shares
have been issued up to the date of the resolution, whether or not it has been decided to issue same, and whether or not calls have been made on all the issued shares.
|
13. |
The increase of share capital shall be in such amount and divided into shares of such nominal value, and with such restrictions and conditions and with such
rights and privileges as the Resolution dealing with the creation of the shares prescribes, and if no provisions are contained in the Resolution, then as the Board of Directors shall prescribe.
|
14. |
Unless otherwise stated in the Resolution approving the increase of the share capital, the new shares shall be subject to those provisions in regard to issue,
allotment, alteration of rights, payment of calls, liens, forfeiture, transfer, transmission and other provisions which apply to the shares of the Company.
|
15. |
By Resolution, the Company may, subject to any applicable provisions of the Companies Law:
|
15.1. |
consolidate its existing share capital, or any part thereof, into shares of a larger denomination than the existing shares;
|
15.2. |
sub-divide its share capital, in whole or in part, into shares of a smaller denomination than the nominal value of the existing shares and without prejudice to
the foregoing, one or more of the shares so created may be granted any preferred or deferred rights or any special rights with regard to dividends, participation in assets upon winding-up, voting and so forth, subject to the provisions of
these Articles;
|
15.3. |
reduce its share capital; or
|
15.4. |
cancel any shares which on the date of passing of the Resolution have not been issued and to reduce its share capital by the amount of such shares.
|
16. |
In the event that the Company shall adopt any of the Resolutions described in Article 15 above, the Board of Directors shall be entitled to prescribe
arrangements necessary in order to resolve any difficulty arising or that are likely to arise in connection with such Resolutions, including, in the event of a consolidation, it shall be entitled to (i) allot, in contemplation of or
subsequent to such consolidation or other action, shares or fractional shares sufficient to preclude or remove fractional share holdings; (ii) redeem, in the case of redeemable shares, and subject to applicable law, such shares or fractional
shares sufficient to preclude or remove fractional share holdings; (iii) round up, round down or round to the nearest whole number, any fractional shares resulting from the consolidation or from any other action which may result in fractional
shares; or (iv) cause the transfer of fractional shares by certain Shareholders to other Shareholders thereof so as to most expediently preclude or remove any fractional shareholdings, and, cause the transferees of such fractional shares to
pay the transferors thereof the fair value thereof, and the Board of Directors is hereby authorized to act in connection with such transfer, as agent for the transferors and transferees of any such fractional shares, with full power of
substitution, for the purposes of implementing the provisions of this Article 16
|
17. |
To the extent shares are certificated, share certificates evidencing title to the shares of the Company shall be issued under the seal or rubber stamp of the
Company, and together with the signatures of two members of the Board of Directors, or one Director together with the Chief Executive Officer, the Chief Financial Officer, the Secretary of the Company or any other person designated by the
Board of Directors. The Board of Directors shall be entitled to decide that the signatures be effected in any mechanical or electronic form, provided that the signature shall be effected under the supervision of the Board of Directors in such
manner as it prescribes.
|
18. |
Every Shareholder shall be entitled, free of charge, to one certificate in respect of all the shares of a single class registered in his name in the Register.
|
19. |
The Board of Directors shall not refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the
opinion of the Board of Directors, unreasonable. Where a Shareholder has sold or transferred some of his shares, he shall be entitled, free of charge, to receive a certificate in respect of his remaining shares, provided that the previous
certificate is delivered to the Company before the issuance of a new certificate.
|
20. |
Every share certificate shall specify the number of the shares in respect of which such certificate is issued and also the amounts which have been paid up in
respect of each share.
|
21. |
No Person shall be recognized by the Company as having any right to a share unless such Person is the registered owner of the shares in the Register. The
Company shall not be bound by and shall not recognize any right or privilege pursuant to the laws of equity, or a fiduciary relationship or a chose in action, future or partial, in any share, or a right or privilege to a fraction of a share,
or (unless these Articles otherwise direct) any other right in respect of a share, except the absolute right to the share as a whole, where same is vested in the owner registered in the Register.
|
22. |
A share certificate registered in the names of two or more persons shall be delivered to one of the joint holders, and the Company shall not be obliged to issue
more than one certificate to all the joint holders of shares and the delivery of such certificate to one of the joint holders shall be deemed to be delivery to all of them.
|
23. |
If a share certificate should be lost, destroyed or defaced, the Board of Directors shall be entitled to issue a new certificate in its place, provided that the
certificate is delivered to it and destroyed by it, or it is proved to the satisfaction of the Board of Directors that the certificate was lost or destroyed and security has been received to its satisfaction in respect of any possible damages
and after payment of such amount as the Board of Directors shall prescribe.
|
24. |
The Board of Directors may from time to time, in its discretion, make calls on Shareholders in respect of amounts which are still unpaid in respect of the
shares held by each of the Shareholders (including premiums), and the terms of issue which do not prescribe that same be paid at fixed times, and every Shareholder shall be obliged to pay the amount of the call made on him, at such time and
at such place as stipulated by the Board of Directors.
|
25. |
In respect of any such call, prior notice of at least fourteen (14) business days shall be given, stating to whom the amount called is to be paid, the time for
payment and the place thereof, provided that prior to the due date for payment of such call, the Board of Directors may, by written notice to the Shareholders to which the call was made, cancel the call or extend the date of payment thereof.
|
26. |
If according to the terms of issue of any share, or otherwise, any amount is required to be paid at a fixed time or in installments at fixed times, whether the
payment is made on account of the share capital in respect of the share or in form of a premium, every such payment or every such installment shall be paid as if it was a call duly made by the Board of Directors, in respect of which notice
was duly given, and all the provisions contained in these Articles in regard to calls shall apply to such amount or to such installment.
|
27. |
Joint holders of a share shall be jointly and severally liable for the payment of all installments and calls due in respect of such share.
|
28. |
In the event that a call or installment due on account of a share is not paid on or before the date fixed for payment thereof, the holder of the share, or the
Person to whom the share has been allotted, shall be obliged to pay linkage differentials and interest on the amount of the call or the installment, at such rate as shall be determined by the Board of Directors, commencing from the date fixed
for the payment thereof and until the date of actual payment. The Board of Directors may, however, waive the payment of the linkage differentials or the interest or part thereof.
|
29. |
A Shareholder shall not be entitled (i) to receive a dividend and (ii) to exercise any right as a Shareholder, including but not limited to, the right to attend
and vote at a General Meeting of any type and to transfer the shares to another; unless he has paid all the calls payable from time to time and which apply to any of his shares, whether he holds same alone or jointly with another, plus
linkage differentials, interest and expenses, if any.
|
30. |
The Board of Directors may, if it deems fit, accept payment from a Shareholder wishing to advance the payment of all moneys which remain unpaid on account of
his shares, or part thereof which are over and above the amounts which have actually been called, and the Board of Directors shall be entitled to pay such Shareholder linkage differentials and interest in respect of the amounts paid in
advance, or that portion thereof which exceeds the amount called for the time being on account of the shares in respect of which the advance payment is made, at such rate as is agreed upon between the Board of Directors and the Shareholder,
with this being in addition to dividends payable (if any) on the paid-up portion of the share in respect of which the advance payment is made.
|
31. |
If a Shareholder fails to make payment of any call or other installment on or before the date fixed for the payment thereof, the Board of Directors may, at any
time thereafter and for as long as the part of the call or installment remains unpaid, serve on such Shareholder a notice demanding that he make payment thereof, together with the linkage differentials and interest at such rate as is
specified by the Board of Directors and all the expenses incurred by the Company in consequence of such non-payment.
|
32. |
The notice shall specify a further date, which shall be at least fourteen (14) business days after the date of the delivery of the notice, and a place or places
at which such call or installment is to be paid, together with linkage differentials and interest and expenses as aforesaid. The notice shall further state that, if the amount is not paid on or before the date specified, and at the place
mentioned in such notice, the shares in respect of which the call was made, or the installment is due, shall be liable to forfeiture.
|
33. |
If the demands contained in such notice are not complied with the Board of Directors may treat the shares in respect of which the notice referred to in Articles
31 and 32 was given as forfeited. Such forfeiture shall include all dividends, bonus shares and other benefits which have been declared in respect of the forfeited shares which have not actually been paid prior to the forfeiture.
|
34. |
Any share so forfeited or waived shall be deemed to be the property of the Company and the Board of Directors shall be entitled, subject to the provisions of
these Articles and the Companies Law, to sell, re-allot or otherwise dispose thereof, as it deems fit, whether the amount paid previously in respect of that share is credited, in whole or in part.
|
35. |
The Board of Directors may, at any time before any share forfeited as aforesaid is sold or re-allotted or otherwise dispose of, cancel the forfeiture on such
conditions as it deems fit.
|
36. |
Any Person whose shares have been forfeited shall cease to be a Shareholder in respect of the forfeited shares, but shall, nonetheless remain liable for the
payment to the Company of all calls, installments, linkage differentials, interest and expenses due on account of or in respect of such shares on the date of forfeiture, in respect of the forfeited shares, together with interest on such
amounts reckoned from the date of forfeiture until the date of payment, at such rate as the Board of Directors shall from time to time specify. However, such Person’s liability shall cease after the Company has received all the amounts called
in respect of the shares as well as any expenses incurred by the Company relating to collecting the amounts called. The Board of Directors shall be entitled to collect the moneys which have been forfeited, or part thereof, as it shall deem
fit, but it shall not be obliged to do so.
|
37. |
The provisions of these Articles in regard to forfeiture shall also apply to cases of non-payment of any amount, which, according to the terms of issue of the
share, or which under the conditions of allotment the due date for payment of which fell on a fixed date, whether this be on account of the nominal value of the share or in the form of a premium, as if such amount was payable pursuant to a
call duly made and notified.
|
38. |
The Company shall have a first and paramount lien over all the shares which have not been fully paid up and which are registered in the name of any Shareholder
(whether individually or jointly with others) and also over the proceeds of the sale thereof, as security for the debts and obligations of such Shareholder to the Company and his contractual engagements with it, either individually or
together with others. This right of lien shall apply whether or not the due date for payment of such debts or the fulfillment or performance of such obligations has arrived, and no rights in equity shall be created in respect of any share,
over which there is a lien as aforesaid. The aforesaid lien shall apply to all dividends or benefits which may be declared, from time to time, on such shares, unless the Board of Directors shall decide otherwise.
|
39. |
In order to foreclose on such lien, the Board of Directors may sell the shares under lien at such time and in such manner as, it shall deem fit, but no share
may be sold unless the period referred to below has elapsed and written notice has been given to the Shareholder, his trustee, liquidator, receiver, the executors of his estate, or anyone who acquires a right to shares in consequence of the
bankruptcy of a Shareholder, as the case may be, stating that the Company intends to sell the shares, if he or they should fail to pay the aforesaid debts, or fail to discharge or fulfill the aforesaid obligations within fourteen (14)
business days from the date of the delivery of the notice.
|
40. |
The net proceeds of any such sale of shares, as contemplated by Article 39 above, after deduction of the expenses of the sale, shall serve for the discharge of
the debts of such shareholder or for performance of such Shareholder’s obligations (including debts, undertakings and contractual engagements the due date for the payment or performance of which has arrived) and the surplus, if any, shall be
paid to the Shareholder, his trustee, liquidator, receiver, guardians, the executors of his estate, or to his successors-in-title.
|
41. |
In every case of a sale following forfeiture or waiver, or for purposes of executing a lien by exercising all of the powers conferred above, the Board of
Directors shall be entitled to appoint a person to sign an instrument of transfer of the shares sold, and to arrange for the registration of the name of the buyer in the Register in respect of the shares sold.
|
42. |
An affidavit signed by the Chairman of the Board of Directors that a particular share of the Company was forfeited, waived or sold by the Company by virtue of a
lien, shall serve as conclusive evidence of the facts contained therein as against any person claiming a right in the share. The purchaser of a share who relies on such affidavit shall not be obliged to investigate whether the sale,
re-allotment or transfer, or the amount of consideration and the manner of application of the proceeds of the sale, were lawfully effected, and after his name has been registered in the Register he shall have a full right of title to the
share and such right shall not be adversely affected by a defect or invalidity which occurred in the forfeiture, waiver, sale, re-allotment or transfer of the share.
|
43. |
No transfer of shares shall be registered unless a proper instrument of transfer is delivered to the Company or, in the case of shares registered with a
transfer agent, delivered to such transfer agent or to such other place specified for this purpose by the Board of Directors. Subject to the provisions of these Articles, an instrument of transfer of a share in the Company shall be signed by
the transferor and the transferee. The Board of Directors may approve other methods of recognizing the transfer of shares in order to facilitate the trading of the Company’s shares on the Nasdaq Global Market or on any other stock exchange.
The transferor shall be deemed to remain the holder of the share up until the time the name of the transferee is registered in the Register in respect of the transferred share.
|
44. |
Insofar as the circumstances permit, the instrument of transfer of a share shall be substantially in the form set out below, or in any other form that the Board
of Directors may approve (the “Deed of Transfer”).
|
45. |
The Company may close the transfer registers and the Register for such period of time as the Board of Directors shall deem fit.
|
46. |
Every instrument of transfer shall be submitted to the Office or to such other place as the Board of Directors shall prescribe, for purposes of registration,
together with the share certificates to be transferred, or if no such certificate was issued, together with a letter of allotment of the shares to be transferred, and/or such other proof as the Board of Directors may demand in regard to the
transferor’s right of title or his right to transfer the shares. The Board of Directors shall have the right to refuse to recognize an assignment of shares until the appropriate securities under the circumstances have been provided, as shall
be determined by the Board of Directors in a specific case or from time to time in general. Instruments of transfer which serve as the basis for transfers that are registered shall remain with the Company.
|
47. |
Every instrument of transfer shall relate to one class of shares only, unless the Board of Directors shall otherwise agree.
|
48. |
The executors of the will or administrator of a deceased Shareholder’s estate (such Shareholder not being one of a joint owners of a share) or, in the absence
of an administrator of the estate or executor of the will, the persons specified in Article 49 below, shall be entitled to demand that the Company recognize them as owners of rights in the share. The provisions of Article 46 above shall
apply, mutatis mutandis, also in regard to this Article.
|
49. |
In the case of the death of one of the holders of a share registered in the names of two or more Persons, the Company shall recognize only the surviving owners
as Persons having rights in the share. However, the aforementioned shall not be construed as releasing the estate of a deceased joint Shareholder from any and all undertakings in respect of the shares. Any Person who shall become an owner of
shares following the death of a Shareholder shall be entitled to be registered as owner of such shares after having presented to an officer of the Company to be designated by the Chief Executive Officer an inheritance order or probation order
or order of appointment of an administrator of estate and any other proof as required - if these are sufficient in the opinion of such officer - testifying to such Person’s right to appear as shareholder in accordance with these Articles, and
which shall testify to his title to such shares. The provisions of Article 46 above shall apply, mutatis mutandis, also in regard to this Article.
|
50. |
The receiver or liquidator of a Shareholder who is a company or the trustee in bankruptcy or the official receiver of a Shareholder who is bankrupt, upon
presenting appropriate proof to the satisfaction of an officer of the Company to be designated by the Chief Executive Officer that such Shareholder has the right to appear in this capacity and which testifies to such Shareholder’s title, may,
with the consent of the Board of Directors (the Board of Directors shall not be obligated to give such consent) be registered as the owner of such shares. Furthermore, such Shareholder may assign such shares in accordance with the rules
prescribed in these Articles. The provisions of Article 46 above shall apply, mutatis mutandis, also in regard to this Article.
|
51. |
A Person entitled to be registered as a Shareholder following assignment pursuant to these Articles shall be entitled, if approved by the Board of Directors and
to the extent and under the conditions prescribed by the Board of Directors, to dividends and any other monies paid in respect of the shares, and shall be entitled to give the Company confirmation of the payments; however, he shall not be
entitled to be present or to vote at any General Meeting of the Company or, subject to the provisions of these Articles, to make use of any rights of Shareholders, until he has been registered as owner of such shares in the Register.
|
52. |
A General Meeting shall be held at least once in every year, not later than 15 (fifteen) months after the last General Meeting, at such time and at such place
as the Board of Directors shall determine. Such General Meeting shall be called an annual meeting, and all other meetings of the Shareholders shall be called extraordinary meetings.
|
53. |
The Board of Directors may call an extraordinary meeting whenever it sees fit to do so.
|
54. |
The Board of Directors shall be obliged to call an extraordinary meeting upon a requisition in writing in accordance with the Companies Law.
|
55. |
The Company shall provide prior notice in regard to the holding of an annual meeting or an extraordinary meeting in accordance with the requirements of these
Articles, the Companies Law and the regulations promulgated thereunder. Subject to the provisions of the Companies Law and the regulations promulgated thereunder, in counting the number of days of prior notice given, the day of publication of
notice shall not be counted, but the day of the meeting shall be counted. The notice shall specify those items and contain such information as shall be required by the Companies Law, the regulations promulgated thereunder and any other
applicable law and regulations.
|
56. |
Any Shareholder (a “Proposing Shareholder”)requesting to add an item to the agenda of a General Meeting may submit such
a request (a “Proposal Request”) in accordance with the Companies Law. Subject to any requirements under the Law, to be considered timely and thereby be added to such agenda, a Proposal Request must be
delivered, either in person or by certified mail, postage prepaid, and received at the Office, (i) in the case of a General Meeting that is an annual meeting, no less than sixty (60) days nor more than one-hundred twenty (120) days prior to
the date of the first anniversary of the preceding year’s annual meeting, provided, however, that, in the event that the date of the annual meeting is advanced more than thirty (30) days prior to or delayed by more than thirty (30) days after
the anniversary of the preceding year’s annual meeting, notice by the Proposing Shareholder to be timely must be so received not earlier than the close of business one-hundred twenty (120) days prior to such annual meeting and not later than
the close of business on the later of ninety (90) days prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made, and (ii) in the case of a General
Meeting that is an extraordinary meeting, no earlier than one-hundred twenty (120) days prior to such extraordinary meeting and no later than sixty (60) days prior to such extraordinary meeting or the tenth (10th) day following the
day on which public announcement of the date of such meeting is first made, subject to applicable law.
|
57. |
Subject to Article 65 below, in the event that the Company has established that an adjourned meeting shall be held on such date which is later than the date
provided for in Section 78(b) of the Companies Law, such later date shall be included in the notice. The Company may add additional places for Shareholders to review the full text of the proposed resolutions, including an internet site. The
notice shall be provided in the manner prescribed below under the heading “Notices” in Articles 128 to 131 below.
|
58. |
No business shall be conducted at a General Meeting unless a quorum is present, and no resolution shall be passed unless a quorum is present at the time the
resolution is voted on. Except in cases where it is otherwise stipulated, a quorum shall be constituted when there are personally present, or represented by proxy, at least two (2) Shareholders who hold, in the aggregate, at least 25% of the
voting rights in the Company. A proxy may be deemed to be two (2) or more Shareholders pursuant to the number of Shareholders he represents.
|
59. |
If within half an hour from the time appointed for the meeting, a quorum is not present, without there being an obligation to notify the Shareholders to that
effect, the meeting shall be adjourned to the same day, in the following week, at the same hour and at the same place or to a later time and date if so specified in the notice of the meeting, unless such day shall fall on a statutory holiday
(either in Israel or in the United States), in which case the meeting will be adjourned to the first business day afterwards which is not a statutory holiday.
|
60. |
The Chairman of the Board of Directors, or any other Person appointed for this purpose by the Board of Directors, shall preside at every General Meeting. If
within fifteen (15) minutes from the time appointed for the meeting, the designated chairman for the meeting shall not be present, the Shareholders present at the meeting shall elect one of their number to serve as chairman of the meeting.
|
61. |
Resolutions at the General Meeting shall be passed in accordance with the definition of “Resolution” set forth in Article 1.1 above, unless otherwise required
by Companies Law or these Articles. Every vote at a General Meeting shall be conducted according to the number of votes to which each Shareholder is entitled on the basis of the number of Ordinary Shares held by such Shareholder (in
accordance with the provisions of Article 7.1 above).
|
62. |
Where a poll has been demanded, the chairman of the meeting shall be entitled - but not obliged - to accede to the demand. Where the chairman of the meeting has
decided to hold a poll, such poll shall be held in such manner, at such time and at such place as the chairman of the meeting directs, either immediately or after an interval or postponement, or in any other way, and the results of the vote
shall be deemed to be the Resolution at the meeting at which the poll was demanded. A person demanding a poll may withdraw his demand prior to the poll being held.
|
63. |
A demand for the holding of a poll shall not prevent the continued business of the meeting on all other questions apart of the question in respect of which a
poll was demanded.
|
64. |
The announcement by the chairman of the meeting that a Resolution has been passed unanimously or by a particular majority, or has been rejected, and a note
recorded to that effect in the Company’s minute book, shall serve as prima facie proof of such fact, and there shall be no necessity for proving the number of votes or the proportion of votes given
for or against the Resolution, unless otherwise required under applicable law and regulation.
|
65. |
The Chairman of a General Meeting at which a quorum is present may, with the consent of holders of a majority of the voting power represented in person and by
proxy and voting on the question of adjournment, adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the
meeting as originally called. Subject to these Articles, it shall not be necessary to give any notice of an adjournment unless the meeting is adjourned for more than twenty-one (21) days, in which case notice thereof shall be given in the
manner required for the meeting as originally called. Where a General Meeting has been adjourned without changing its agenda, to a date which is not more than twenty-one (21) days, notices shall be given for the new date, as early as
possible, and by no later than seventy-two (72) hours before the General Meeting.
|
66. |
The voting rights of every shareholder entitled to vote at a General Meeting shall be as set forth in Article 7.1 of these Articles.
|
67. |
In the case of joint Shareholders, the vote of the senior joint holder, given personally or by proxy, shall be accepted, to the exclusion of the vote of the
remaining joint Shareholders, and for these purposes the senior of the joint Shareholders shall be the Person amongst the joint holders whose name appears first in the Register.
|
68. |
A Shareholder who is an Incapacitated Person may vote solely through his guardian or other person who fulfills the function of such guardian and who was
appointed by a court, and any guardian or other person as aforesaid shall be entitled to vote by way of a proxy, or in such manner as the court directs.
|
69. |
Any corporation which is a Shareholder of the Company shall be entitled, by way of resolution of its board of directors or another organ which manages said
corporation, to appoint such person which it deems fit, whether or not such person is a Shareholder of the Company, to act as its representative at any General Meeting of the Company or at a meeting of a class of shares in the Company which
such corporation is entitled to attend and to vote thereat, and the appointed as aforesaid shall be entitled, on behalf of the corporation whom he represents, to exercise all of the same powers and authorities which the corporation itself
could have exercised had it been a natural person holding shares of the Company.
|
70. |
Every Shareholder who is entitled to attend and vote at a General Meeting of the Company, shall be entitled to appoint a proxy. A proxy can be appointed by more
than one Shareholder, and vote in different ways on behalf of each principal.
|
71. |
The instrument appointing a proxy, or a copy thereof certified by an attorney, shall be lodged at the Office, or at such other place as the Board of Directors
shall specify, not less than forty-eight (48) hours prior to the meeting at which the proxy intends to vote based on such instrument of proxy. Notwithstanding the above, the chairman of the meeting shall have the right to waive the time
requirement provided above with respect to all instruments of proxies and to accept any and all instruments of proxy until the beginning of a General Meeting. A document appointing a proxy shall be valid for every adjourned meeting of the
meeting to which the document relates.
|
72. |
Every instrument appointing a proxy, whether for a meeting specifically indicated, or otherwise, shall, as far as circumstances permit, be substantially in the
following form, or in any other form approved by the Board of Directors:
|
73. |
No Shareholder shall be entitled to vote at a General Meeting unless he has paid all of the calls and all of the amounts due from him, for the time being, in
respect of his shares.
|
74. |
A vote given in accordance with the instructions contained in an instrument appointing a proxy shall be valid notwithstanding the death or bankruptcy of the
appointer, or the revocation of the proxy, or the transfer of the share in respect of which the vote was given as aforesaid, unless notice in writing of the death, revocation or transfer is received at the Office, or by the chairman of the
meeting, prior to such vote.
|
75. |
Subject to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the chairman of the meeting,
subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such
instrument was signed) or of an instrument appointing a different proxy, provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked
thereby as referred to in Article 71 hereof, or (ii) if the appointing shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the chairman of such meeting of written notice from such
shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation
of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article
75 at or prior to the time such vote was cast.
|
76. |
Unless otherwise resolved by a Resolution, the prescribed number of Directors of the Company shall be between five (5) and nine (9) (including the External
Directors), as may be fixed, from time to time, by the Board of Directors. At any time the minimum number of Directors (other than the External Directors) shall not fall below three (3). Any Director shall be eligible for re-election upon
termination of his term of office, subject to applicable law.
|
77. |
77.1. |
Prior to every annual General Meeting of the Company, the Board of Directors of the Company (or a Committee of Directors)
shall select, via a resolution adopted by a majority of the Board of Directors (or such committee), a number of persons to be proposed to the Shareholders for election as directors of the Company at such annual General
Meeting for service until the annual General Meeting to be held in the next year following the year of their election (the “Nominees”). Any shareholder entitled under applicable law to
nominate one or more persons for election as directors at a General Meeting (each such person, an “Alternate Nominee”) may
make such nomination only if a written notice of such shareholder’s intent to make such nomination or nominations has been given to the Secretary of the Company (or, if there is no such Secretary, the Chief Executive
Officer). Each such notice shall set forth: (a) the name and address of the shareholder who intends to make the nomination and of the Alternate Nominees; (b) a representation that the shareholder is a holder of record of
shares of the Company entitled to vote at such meeting (including the number of shares held of record by the shareholder) and intends to appear in person or by proxy at the meeting to nominate the Alternate Nominees; (c) a
description of all arrangements or understandings between the shareholder and each Alternate Nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be
made by the shareholder; and (d) the consent of each Alternate Nominee to serve as a director of the Company if so elected and a declaration signed by each Alternate Nominee declaring that there is no limitation under the
Companies Law for the appointment of such a nominee and that all of the information that is required under the Companies Law to be provided to the Company in connection with such an appointment has been provided. The Board
of Directors may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.
|
77.2. |
The Nominees or Alternate Nominees shall be elected by a Resolution at the annual General Meeting at which
they are subject to election.
|
77.3. |
Every director shall hold office until the end of the next annual General Meeting following the annual
General Meeting at which he was elected, unless his office is vacated in accordance with Article 79 or Article 82 below. If, at an annual General Meeting, no Nominees or Alternate Nominees are elected,
the directors then in office shall continue to hold office until the convening of a General Meeting at which Nominees or Alternate Nominees shall be elected.
|
77.4. |
If the office(s) of members(s) of the Board of Directors shall be vacated, the remaining members of
the Board of Directors shall be entitled to appoint additional director(s) in place of the director(s) whose office(s) have been vacated, for a term of office equal to the remaining period of the term
of office of the director(s) whose office(s) have been vacated.
|
78. |
The Directors in their capacity as such shall be entitled to receive remuneration as shall be determined in compliance with the Companies Law and the
regulations promulgated thereunder. The conditions (including remuneration) of the terms of office of members of the Board of Directors shall be decided by the Board of Directors and/or any committee thereof, but the same shall be valid only
if ratified in the manner required under the Companies Law. The remuneration of Directors may be fixed as an overall payment or other consideration and/or as a payment or other consideration in respect of attendance at meetings of the Board
of Directors. In addition to his remuneration, each Director shall be entitled to be reimbursed, retroactively or in advance, in respect of his reasonable expenses connected with performing his functions and services as a Director. Such
entitlement shall be determined in accordance with, and shall be subject to, a specific resolution or policy adopted by the Board of Directors regarding such matter and in accordance with the requirements of applicable law.
|
79. |
79.1. |
Subject to the provisions of the Companies Law with regard to External Directors and subject to Article 77 above
and Article 82 below, the office of a member of the Board of Directors shall be vacated in any one of the following events:
|
79.1.1. |
if he resigns his office by way of a letter signed by him, lodged at the Office;
|
79.1.2. |
if he is declared bankrupt;
|
79.1.3. |
if he becomes insane or unsound of mind;
|
79.1.4. |
upon his death;
|
79.1.5. |
if he is prevented by applicable law from serving as a Director of the Company;
|
79.1.6. |
if the Board terminates his office according to Section 231 of the Companies Law;
|
79.1.7. |
if a court order is given in accordance with Section 233 of the Companies Law;
|
79.1.8. |
if he is removed from office by a Resolution at a General Meeting of the Company adopted by a majority of the voting power in the Company; or
|
79.1.9. |
if his period of office has terminated in accordance with the provisions of these Articles.
|
79.2. |
If the office of a member of the Board of Directors should be vacated, the remaining members of the Board of
Directors shall be entitled to act for all purposes, for as long as their number does not fall below the minimum, for the time being, specified for the Directors, as prescribed in Article 76 above. Should their
number fall below the aforesaid minimum, the Directors shall not be entitled to act, except for the appointment of additional directors, or for the purpose of calling a General Meeting for the appointment of
additional directors, or for the purpose of calling a General Meeting for the appointment of a new Board of Directors.
|
79.3. |
The office of an External Director shall be vacated only in accordance with the provisions
for the vacation of office and the removal of External Directors under the Companies Law.
|
80.1 |
Subject to any mandatory provisions of applicable law, a Director shall not be disqualified by virtue of
his office from holding another office in the Company or in any other company in which the Company is a shareholder or in which it has any other form of interest, or of entering into a contract with the
Company, either as seller or buyer or otherwise. Likewise, no contract made by the Company or on its behalf in which a Director has any form of interest may be nullified and a Director shall not be obliged to
account to the Company for any profit deriving from such office, or resulting from such contract, merely by virtue of the fact that he serves as a Director or by reason of the fiduciary relationship thereby
created, but such Director shall be obliged to disclose to the Board of Directors the nature of any such interest at the first opportunity.
A general notice to the effect that a Director is a shareholder or has any other form of interest in a
particular firm or a particular company and that he must be deemed to have an interest in any business with such firm or company shall be deemed to be adequate disclosure for purposes of this Article in
relation to such Director, and after such general notice has been given, such Director shall not be obliged to give special notice in relation to any particular business with such firm or such company.
|
80.2 |
Subject to the provisions of the Companies Law and these Articles, the Company shall be entitled to enter
into a transaction in which an Office Holder of the Company has a personal interest, directly or indirectly, and may enter into any contract or otherwise transact any business with any third party in which
contract or business an Office Holder has a personal interest, directly or indirectly.
|
81. |
The Board of Directors shall elect one (1) or more of its members to serve as the Chairman of the Board of Directors (the “Chairman
of the Board of Directors”), provided that, subject to the provisions of Section 121(c) of the Companies Law, the Chief Executive Officer of the Company shall not serve as Chairman of the Board of Directors. The office of Chairman of
the Board of Directors shall be vacated in each of the cases mentioned in Articles 79.1 above and 82 below. The Board of Directors may also elect one or more members to serve as Vice Chairman, who shall have such duties and authorities as the
Board of Directors may assign to him or her.
|
82. |
Subject to the relevant provisions of the Companies Law, the Company may, in a General Meeting, by a Resolution adopted by a majority of the voting power in the
Company, dismiss any Director, prior to the end of his term of office and the Board of Directors shall be entitled, by regular majority, with the exception of the External Directors who shall be appointed and removed in accordance with the
Companies Law, to appoint another individual in his place as a Director. The individual so appointed shall hold such office only for that period of time during which the director whom he replaces would have held office.
|
83. |
A Director shall not be obliged to hold any share in the Company.
|
84.1. |
The Board of Directors shall, from time to time, appoint a Chief Executive Officer and subject to the
provisions of the Companies Law delineate his powers and authorities and his remuneration. Subject to any contract between the Chief Executive Officer and the Company, the Board of Directors may dismiss
him or replace him at any time it deems fit.
|
84.2. |
A Chief Executive Officer need not be a Director or Shareholder.
Subject to the provisions of any contract between the Chief Executive Officer
and the Company, if the Chief Executive Officer is also a Director, all of the same provisions with regard to appointment, resignation and removal from office shall apply to the
Chief Executive Officer in his capacity as a Director, as apply to the Company's other Directors.
|
84.3. |
The Board of Directors shall be entitled from time to time
to delegate to the Chief Executive Officer for the time being such of the powers it has pursuant to these Articles as they deem appropriate, and the Board of
Directors shall be entitled to grant such powers for such period and for such purposes and on such conditions and with such restrictions as it deem appropriate,
and it shall be entitled to grant such powers without renouncing the powers and authorities of the Board of Directors in such regard, and it may, from time to
time, revoke, annul and alter such delegated powers and authorities, in whole or in part.
|
84.4. |
Subject to the provisions of any applicable law, the remuneration of the Chief Executive Officer shall be fixed from time to time by the Board of Directors
(and, so long as required by the Companies Law, shall be approved by the Compensation Committee and by the Shareholders unless exempted from Shareholders approval) and such remuneration may be in the form of a fixed salary or commissions or a
participation in profits, or in any other manner which may be decided by the Board of Directors (and approved according to this Article 84.4).
|
85.1. |
The Board of Directors shall convene for a meeting at least once every fiscal quarter.
|
85.2. |
The Board of Directors may meet in order to exercise its powers pursuant to Section 92 of the Companies Law, including without
limitation to supervise the Company’s affairs, and it may, subject to the provisions of the Companies Law, adjourn its meetings and regulate its proceedings and operations as it deems fit. It may also prescribe the quorum required for
the conduct of business. Until otherwise decided a quorum shall be constituted if a majority of the Directors holding office for the time being are present.
|
85.3. |
Should a Director or Directors be barred from being present and voting at a meeting of the Board of Directors pursuant to Section
278 of the Companies Law, the quorum shall be a majority of the Directors entitled to be present and to vote at the meeting of the Board of Directors.
|
86. |
Any Director, the Chief Executive Officer or the auditor of the Company in the event stipulated in Section 169 of the Companies Law, may, at any time, demand
the convening of a meeting of the Board of Directors. The Chairman of the Board shall be obliged, on such demand, to call such meeting on the date requested by the Director, the Chief Executive Officer or the auditor of the Company soliciting
such a meeting, provided that proper notice pursuant to Article 87 is given.
|
87. |
Every Director shall be entitled to receive notice of meetings of the Board of Directors, and such notice may be in writing or by facsimile, or electronic mail,
sent to the last address (whether physical or electronic) or facsimile number given by the Director for purposes of receiving notices, provided that the notice shall be given at least a reasonable amount of time prior to the meeting and in no
event less than 48 (forty eight) hours prior notice, unless the urgency of the matter(s) to be discussed at the meeting reasonably require(s) a shorter notice period.
|
88. |
Every meeting of the Board of Directors at which a quorum is present shall have all the powers and authorities vested for the time being in the Board of
Directors.
|
89. |
Questions which arise at meetings of the Board of Directors shall be decided by a simple majority of the members of the Board of Directors attending such
meeting and voting on such matter. In the case of an equality of votes of the Board of Directors, the Chairman of the Board of Directors shall not have a second or casting vote, and the proposal shall be deemed to be defeated.
|
90. |
The Board of Directors may adopt resolutions, without actually convening a meeting of the Board of Directors, provided that all the Directors entitled to
participate in the meeting and to vote on the subject brought for decision agree thereto. If resolutions are made as stated in this Article 90, the Chairman of the Board of Directors shall record minutes of the decisions stating the manner of
voting of each Director on the subjects brought for decision, as well as the fact that all the Directors agreed to take the decision without actually convening.
|
91. |
The Board of Directors may hold meetings by use of any means of communication, on condition that all participating Directors can hear each other at the same
time. In the case of a resolution passed by way of a telephone call or any such other means of communication, a copy of the text of the resolution shall be sent, as soon as possible thereafter, to the Directors.
|
92. |
The supervision of the Company’s affairs shall be in the hands of the Board of Directors, which shall be entitled to exercise all of the powers and authorities
to perform any act and deed which the Company is entitled to exercise and to perform in accordance with these Articles or according to the Companies Law, and in respect of which there is no provision or requirement in these Articles, or in
the Companies Law or/and in the U.S. Rules, that such powers and authorities may be exercised or done by the Shareholders in a General Meeting or by a Committee of Directors.
|
93. |
The Board of Directors may, as it deems fit and subject to any applicable law, delegate to a committee (a “Committee of
Directors”) certain of its powers and authorities, in whole or in part (as appropriate). The curtailment or revocation of the powers and authorities of a Committee of Directors by the Board of Directors shall not invalidate a prior
act of such Committee of Directors or an act taken in accordance with its instructions, which would have been valid had the powers and authorities of the Committee of Directors not been altered or revoked by the Board of Directors. Subject to
applicable law, a Committee of Directors may be comprised of one (1) Director or of several Directors, and in the case of a Committee of Directors that is appointed to advise the Board of Directors only, persons who are not Directors may be
appointed to it.
|
94. |
The meetings and proceedings of every such Committee of Directors which is comprised of 2 (two) or more members shall be conducted in accordance with the
provisions contained in these Articles in regard to the conduct of meetings and proceedings of the Board of Directors to the extent that the same are suitable for such committee, and so long as no provisions have been adopted in replacement
thereof by the Board of Directors.
|
95. |
Subject to the Companies Law, all acts taken in good faith by the Board of Directors and/or a Committee of Directors or by an individual acting as a member
thereof shall be valid even if it is subsequently discovered that there was a defect in the appointment of the Board of Directors, the Committee of Directors or the member, as the case may be, or that the members, or one of them, was/were
disqualified from being appointed as a Director/s or to a Committee of Directors.
|
96.1. |
The Board of Directors or any Committee of Directors may ratify any act the performance of which at the time of the ratification was
within the scope of the authority of the Board of Directors or the relevant Committee of Directors.
|
96.2. |
The General Meeting shall be entitled to ratify any act taken by the Board of Directors and/or any Committee of Directors without
authority or which was tainted by some other defect.
|
96.3. |
From the time of the ratification, every act ratified as aforesaid, shall be treated as though lawfully performed from the outset.
|
97. |
The Board of Directors may, from time to time, in its absolute discretion, borrow or secure any amounts of money required by the Company for the conduct of its
business.
|
98. |
The Board of Directors shall be entitled to raise or secure the repayment of an amount obtained by them, in such way and on such conditions and times as they
deem fit. The Board of Directors shall be entitled to issue documents of undertaking, such as options, debentures or debenture stock, whether linked or redeemable, convertible debentures or debentures convertible into other securities, or
debentures which carry a right to purchase shares or to purchase other securities, or any mortgage, pledge, collateral or other charge over the property of the Company and its undertaking, in whole or in part, whether present or future,
including the uncalled share capital or the share capital which has been called but not yet paid.
|
99. |
Subject to any other resolution on the subject passed by the Board of Directors, the Company shall be bound only pursuant to a document in writing bearing its
seal or its rubber stamp or its printed name, and the signature of whomever may be authorized by the Board of Directors, which shall be entitled to empower any person, either alone or jointly with another, even if he is not a Shareholder or a
Director, to sign and act in the name and on behalf of the Company.
|
100. |
The Board of Directors shall be entitled to prescribe separate signing power in regard to different businesses of the Company and in respect of the limit of the
amounts in respect of which various persons shall be authorized to sign.
|
101. |
The Board of Directors shall be entitled, from time to time, to appoint, or to delegate to the Chief Executive Officer, either alone or together with other
persons designated by the Board of Directors, the ability to appoint Office Holders (other than Directors), a Secretary for the Company, employees and agents to such permanent, temporary or special positions, and to specify and change their
titles, authorities and duties, and may set, or delegate to the Chief Executive Officer, either alone or together with other persons designated by the Board of Directors, the ability to set salaries, bonuses and other compensation of any
employee or agent who is not an Office Holder. Salaries, bonuses and compensation of Office Holders who are not Directors shall be determined and approved by the Chief Executive Officer, and/or in such other manner as may be required from
time to time under the Companies Law. The Board of Directors, or the Chief Executive Officer, either alone or together with other persons designated by the Board of Directors, (in the case of any Office Holder, employee or agent appointed
thereby), shall be entitled at any time, in its, his or their (as applicable) sole and absolute discretion, to terminate the services of one of more of the foregoing persons (in the case of a Director, however, subject to compliance with
Article 79 above), subject to any other requirements under applicable law.
|
102. |
The Board of Directors and the Chief Executive Officer may from time to time and at any time, subject to their powers under these Articles and the Companies
Law, empower any person to serve as representative of the Company for such purposes and with such powers and authorities, instructions and discretions for such period and subject to such conditions as the Board of Directors (or the Chief
Executive Officer, as the case may be) shall deem appropriate. Consistent with the preceding sentence, the Board of Directors (or the Chief Executive Officer, as the case may be) may grant such person, inter
alia, the power to transfer the authority, powers and discretions vested in him, in whole or in part. The Board of Directors may (or the Chief Executive Officer, as the case may be), from time to time, revoke, annul, vary or change
any such power or authority, or all such powers or authorities collectively.
|
103. |
Unless otherwise permitted by the Companies Law, no dividends shall be paid other than out of the Company’s profits available for distribution as set forth in
the Companies Law.
|
104. |
The Board of Directors may decide on the payment of a dividend or on the distribution of bonus shares.
|
105. |
A dividend in cash or bonus shares shall be paid or distributed, as the case may be, equally to the holders of the Ordinary Shares registered in the Register,
pro rata to the nominal amount of capital paid up or credited as paid up on par value of the shares, without reference to any premium which may have been paid thereon. However, whenever the rights attached to any shares or the terms of issue
of the shares do not provide otherwise, an amount paid on account of a share prior to the payment thereof having been called, or prior to the due date for payment thereof, and on which the Company is paying interest, shall not be taken into
account for purposes of this Article as an amount paid-up on account of the share.
|
106. |
Unless other instructions are given, it shall be permissible to pay any dividend by way of a check or payment order to be sent by post to the registered address
of the Shareholder or the Person entitled thereto, or in the case of joint Shareholders being registered, to the Shareholder whose name appears first in the Register in relation to the joint shareholding. Every such check shall be made in
favor of the Person to whom it is sent. A receipt by the Person whose name, on the date of declaration of the dividend, was registered in the Register as the owner of the shares, or in the case of joint holders, by one of the joint holders,
shall serve as a discharge with regard to all the payments made in connection with such share.
|
107. |
Unless otherwise specified in the terms of issue of shares or securities convertible into, or which grant a right to purchase, shares, any shares that are fully
paid-up or credited as paid-up shall at any time confer on their holders the right to participate in the full dividends and in any other distribution for which the determining date for the right to receive the same is the date at which the
aforesaid shares were fully paid-up or credited as fully paid-up, as the case may be, or subsequent to such date.
|
108. |
A dividend or other beneficial rights in respect of shares shall not bear interest.
|
109. |
The Board of Directors shall be entitled to deduct from any dividend or other beneficial rights, all amounts of money which the holder of the share in respect
of which the dividend is payable or in respect of which the other beneficial rights were given, may owe to the Company in respect of such share, whether or not the due date for payment thereof has arrived.
|
110. |
The Board of Directors shall be entitled to retain any dividend or bonus shares or other beneficial rights in respect of a share in relation to which the
Company has a lien, and to utilize any such amount or the proceeds received from the sale of any bonus shares or other beneficial rights, for the discharge of the debts or liabilities in respect of which the Company has a lien.
|
111. |
The Board of Directors may decide that a dividend is to be paid, in whole or in part, by way of a distribution of assets of the Company in kind, including by
way of debentures or debenture stock of the Company, or shares or debentures or debenture stock of any other company, or in any other way.
|
112. |
112.1. |
The Board of Directors may, at any time and from time to time, decide that any portion of the amounts standing for the time being to the credit of any capital
fund (including a fund created as a result of a revaluation of the assets of the Company), or which are held by the Company as profits available for distribution, shall be capitalized for distribution subject to and in accordance with the
provisions of the Companies Law and of these Articles, amongst those Shareholders who are entitled thereto and pro rata to their entitlement under these Articles, provided that the same shall not be paid in cash but shall serve for the
payment up in full either at par or with a premium as prescribed by the Company, of shares which have not yet been issued or of debentures of the Company which shall be allotted and distributed amongst the Shareholders in the aforesaid ratio
as fully paid-up shares or debentures.
|
112.2. |
The Board of Directors shall be entitled to distribute bonus shares and to decide that the bonus shares shall be of the same class which confers on the
Shareholders or the Persons entitled thereto the right to participate in the distribution of bonus shares, or may decide that the bonus shares shall be of a uniform class to be distributed to each of the Shareholders or Persons entitled to
shares as aforesaid, without reference to the class of shares conferring the right to participate in the distribution on the holders of the shares or the Persons entitled thereto as aforesaid.
|
113.1. |
In every case that the Company issues bonus shares by way of a capitalization of profits or funds at a time at which securities issued by the Company are in
circulation and confer on the holders thereof rights to convert the same into shares in the share capital of the Company, or options to purchase shares in the share capital of the Company (such rights of conversion or options shall henceforth
be referred to as the “Rights”), the Board of Directors shall be entitled (in a case that the Rights or part thereof shall not be otherwise adjusted in accordance with the terms of their issue) to
transfer to a special fund designated for the distribution of bonus shares in the future (to be called by any name that the Board of Directors may decide on and which shall henceforth be referred to as the “Special
Fund”) an amount equivalent to the nominal amount of the share capital to which some or all of the Rights holders would have been entitled as a result of the issue of bonus shares, had they exercised their Rights prior to the
determining date for the right to receive bonus shares, including rights to fractions of bonus shares, and in the case of a second or additional distribution of bonus shares in respect of which the Company acts pursuant to this Article,
including entitlement stemming from a previous distribution of bonus shares.
|
113.2. |
In the case of the allotment of shares by the Company as a consequence of the exercise of entitlement by the owners of shares in those cases in which the Board
of Directors has made a transfer to the Special Fund in respect of the Rights pursuant to Article 113.1 above, the Board of Directors shall allot to each such shareholder, in addition to the shares to which he is entitled by virtue of having
exercised his rights, such number of fully paid-up shares the nominal value of which is equivalent to the amount transferred to the Special Fund in respect of his rights, by way of a capitalization to be effected by the Board of Directors of
an appropriate amount out of the Special Fund. The Board of Directors shall be entitled to decide on the manner of dealing with rights to fractions of shares in its sole discretion.
|
113.3. |
If after any transfer to the Special Fund has been made the Rights should lapse, or the period should end for the exercise of Rights in respect of which the
transfer was effected without such Rights being exercised, then any amount which was transferred to the Special Fund in respect of the aforesaid unexercised Rights shall be released from the Special Fund, and the Company may deal with the
amount so released in any manner it would have been entitled to deal therewith had such amount not been transferred to the Special Fund.
|
114. |
For the implementation of any resolution regarding a distribution of shares or debentures by way of a capitalization of profits as aforesaid, the Board of
Directors may:
|
114.1. |
Resolve any difficulty which arises or may arise in regard to the distribution in such manner as it deems fit and may take all of the steps that it deems
appropriate in order to overcome such difficulty.
|
114.2. |
Issue certificates in respect of fractions of shares, or decide that fractions of less than an amount to be decided by the Board of Directors shall not be taken
into account for purposes of adjusting the rights of the Shareholders or may sell the fractions of shares and pay the proceeds (net) to the Persons entitled thereto.
|
114.3. |
Sign, or appoint a Person to sign, on behalf of the Shareholders on any contract or other document which may be required for purposes of giving effect to the
distribution, and, in particular, shall be entitled to sign or appoint a Person who shall be entitled to appoint and submit a contract as referred to in Section 291 of the Companies Law.
|
114.4. |
Make any arrangement or other scheme which is required in the opinion of the Board of Directors in order to facilitate the distribution.
|
115. |
The Board of Directors shall be entitled, as it deems appropriate and expedient, to appoint trustees or nominees for those registered Shareholders who have
failed to notify the Company of a change of their address and who have not applied to the Company in order to receive dividends, shares or debentures out of capital, or other benefits during the aforesaid period. Such trustees or nominees
shall be appointed for the use, collection or receipt of dividends, shares or debentures out of capital and rights to subscribe for shares which have not yet been issued and which are offered to the Shareholders but they shall not be entitled
to transfer the shares in respect of which they were appointed, or to vote on the basis of holding such shares. In all of the terms and conditions governing such trusts and the appointment of such nominees it shall be stipulated by the
Company that upon the first demand by a beneficial holder of a share being held by the trustee or nominee, such trustee or nominee shall be obliged to return to such shareholder the share in question and/or all of those rights held by it on
the Shareholder’s behalf (all as the case may be). Any act or arrangement effected by any such nominees or trustee and any agreement between the Board of Directors and a nominee or trustee shall be valid and binding in all respects.
|
116. |
The Board of Directors may from time to time prescribe the manner for payment of dividends or the distribution of bonus shares and the arrangement connected
therewith. Without derogating from the generality of the foregoing, the Board of Directors shall be entitled to pay any dividends or moneys in respect of shares by sending a check via the mails to the address of the holder of registered
shares according to the address registered in the register of Shareholders. Any dispatch of a check as aforesaid shall be done at the risk of the shareholder.
|
117. |
If two (2) or more Persons are registered as joint holders of a share, each of them shall be entitled to give a valid receipt in respect of any dividend, share
or debenture out of capital, or other moneys, or benefits, paid or granted in respect of such share.
|
118. |
The Board of Directors shall comply with all the provisions of the Companies Law in regard to the recording of charges and the keeping and maintaining of a
register of directors, register of Shareholders and register of charges.
|
119. |
Any book, register and record that the Company is obliged to keep in accordance with the Companies Law or pursuant to these Articles shall be recorded in a
regular book, or by digital, electronic or other means, as the Board of Directors shall decide.
|
120. |
Subject to and in accordance with the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any
place outside Israel as the Board of Directors may deem fit, and, subject to all applicable requirements of the Companies Law, the Board of Directors may from time to time adopt such rules and procedures as it may deem fit in connection with
the keeping of such supplementary registers.
|
121. |
The Board of Directors shall keep proper books of account in accordance with the provisions of the Companies Law. The books of account shall be kept at the
Office, or at such other place or places as the Board of Directors shall deem appropriate, and shall at all times be open to the inspection of members of the Board of Directors. A Shareholder of the Company who is not a member of the Board of
Directors shall not have the right to inspect any books or accounts or documents of the Company, unless such right has been expressly granted to him by the Companies Law, or if he has been permitted to do so by the Board of Directors or by
the Shareholders based on a Resolution adopted at a General Meeting.
|
122. |
[RESERVED]
|
123. |
At least once each year the accounts of the Company and the correctness of the statement of income and the balance sheet shall be audited and confirmed by an
independent auditor or auditors.
|
124. |
The Company shall, in an annual General Meeting, appoint an independent auditor or auditors who shall hold such position until the next annual General Meeting,
and their appointment, remuneration and rights and duties shall be subject to the provisions of the Companies Law, provided, however, that in exercising its authority to fix the remuneration of the auditor(s), the Shareholders in an annual
General Meeting may, by a Resolution, act (and in the absence of any action in connection therewith shall be deemed to have so acted) to authorize the Board of Directors to fix such remuneration subject to such criteria or standards, if any,
as may be provided in such Resolution, and if no such criteria or standards are so provided, such remuneration shall be fixed in an amount commensurate with both the volume and nature of the services rendered by the auditor(s). By an act
appointing such auditors, the Company may appoint the auditor(s) to serve for a period of up to the end of completion of the audit of the yearly financial statements for the three (3) year period then ended.
|
125. |
The auditors shall be entitled to receive notices of every General Meeting of the Company and to attend such meetings and to express their opinions on all
matters pertaining to their function as the auditors of the Company.
|
126. |
Subject to the provisions of the Companies Law and the U.S. Rules, any act carried out by the auditors of the Company shall be valid as against any person doing
business in good faith with the Company, notwithstanding any defect in the appointment or qualification of the auditors.
|
127. |
For as long as the Company is a Public Company, as defined in the Companies Law, it shall appoint an internal auditor possessing the authorities set forth in
the Companies Law. The internal auditor of the Company shall present all of its proposed work plans to the Audit Committee of the Board of Directors, which shall have the authority to approve them, subject to any modifications in its
discretion.
|
128.1. |
The Company may serve any written notice or other document on a Shareholder by way of delivery by hand, by facsimile transmission or by dispatch by prepaid
registered mail to his address as recorded in the Register, or if there is no such recorded address, to the address given by him to the Company for the sending of notices to him. Notwithstanding the foregoing or any other provision to the
contrary contained herein, notices or any other information or documents required to be delivered to a Shareholder shall be deemed to have been duly delivered if submitted, published, filed or lodged in any manner prescribed by applicable
law. With respect to the manner of providing such notices or other disclosures, the Company may distinguish between the Shareholders listed on its regular Registry and those listed in any “additional registry”, as defined in Section 138(a) of
the Companies Law, administered by a transfer agent or stock exchange registration company.
|
128.2. |
Any Shareholder may serve any written notice or other document on the Company by way of delivery by hand at the Office, by facsimile or email transmission to
the Company or by dispatch by prepaid registered mail to the Company at the Office.
|
128.3. |
Any notice or document which is delivered or sent to a Shareholder in accordance with these Articles shall be deemed to have been duly delivered and sent in
respect of the shares held by him (whether in respect of shares held by him alone or jointly with others), notwithstanding the fact that such Shareholder has died or been declared bankrupt at such time (whether or not the Company knew of his
death or bankruptcy), and shall be deemed to be sufficient delivery or dispatch to heirs, trustees, administrators or transferees and any other persons (if any) who have a right in the shares.
|
128.4. |
Any such notice or other document shall be deemed to have been served:
|
128.4.1. |
in the case of mailing, 48 hours after it has been posted, or when actually received by the addressee if sooner than 48 hours after it has been posted;
|
128.4.2. |
in the case of overnight air courier, on the next day following the day sent, with receipt confirmed by the courier, or when actually received by the addressee
if sooner;
|
128.4.3. |
in the case of personal delivery, when actually tendered in person to such Shareholder;
|
128.4.4. |
in the case of facsimile or other electronic transmission (including email), the next day following the date on which the sender receives automatic electronic
confirmation by the recipient’s facsimile machine or computer or other device that such notice was received by the addressee; or
|
128.4.5. |
in the case a notice is, in fact, received by the addressee, when received, notwithstanding that it was defectively addressed or failed, in some other respect,
to comply with the provisions of this Article 128.
|
129. |
Any Shareholder whose address is not described in the Register, and who shall not have designated in writing an address for the receipt of notices, shall not be
entitled to receive any notice from the Company. In the case of joint holders of a share, the Company shall be entitled to deliver a notice by dispatch to the joint holder whose name stands first in the Register in respect of such share.
|
130. |
Whenever it is necessary to give notice of a particular number of days or a notice for another period, the day of delivery shall be counted in the number of
calendar days or the period, unless otherwise specified.
|
131. |
Notwithstanding anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required to be set forth in
such notice under these Articles, which is published, within the time otherwise required for giving notice of such meeting, in:
|
131.1. |
at least two daily newspapers in the State of Israel shall be deemed to be notice of such meeting duly given, for the purposes of these Articles, to any
Shareholder whose address as registered in the Register (or as designated in writing for the receipt of notices and other documents) is located in the State of Israel; and
|
131.2. |
one daily newspaper in New York, NY, United States, and in one international wire service shall be deemed to be notice of such meeting duly given, for the
purposes of these Articles, to any shareholder whose address as registered in the Register (or as designated in writing for the receipt of notices and other documents) is located outside the State of Israel.
|
132. |
Subject to the provisions of the Companies Law, the Company shall be entitled to enter into a contract to insure all or part of the liability of an Office
Holder of the Company, imposed on him in consequence of an act which he has performed by virtue of being an Office Holder, in respect of any of the following:
|
132.1. |
The breach of a duty of care to the Company or to any other Person;
|
132.2. |
The breach of a fiduciary duty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds for believing that the action
would not adversely affect the best interests of the Company;
|
132.3. |
A pecuniary liability imposed on him in favor of any other person in respect of an act done in his capacity as an Office Holder.
|
132.4. |
Any other circumstances arising under the law with respect to which the Company may, or will be able to, insure an Office Holder.
|
133. |
Subject to the provisions of the Companies Law, the Company shall be entitled to indemnify an Office Holder of the Company, to the fullest extent permitted by
applicable law. Subject to the provisions of the Companies Law, including the receipt of all approvals as required therein or under any applicable law, the Company may resolve retroactively to indemnify an Office Holder with respect to the
following liabilities and expenses, provided, in each of the below cases, that such liabilities or expenses were incurred by such Office Holder in such Office Holder’s capacity as an Office Holder of the Company:
|
133.1. |
a monetary liability imposed on him in favor of a third party in any judgment, including any settlement confirmed as judgment and an arbitrator’s award which
has been confirmed by the court, in respect of an act performed by the Office Holder by virtue of the Office Holder being an Office Holder of the Company; provided, however, that: (a) any indemnification undertaking with respect to the
foregoing shall be limited (i) to events which, in the opinion of the Board of Directors, are foreseeable in light of the Company’s actual operations at the time of the granting of the indemnification undertaking, and (ii) to an amount or by
criteria determined by the Board of Directors to be reasonable in the given circumstances; and (b) the events that in the opinion of the Board of Directors are foreseeable in light of the Company’s actual operations at the time of the
granting of the indemnification undertaking are listed in the indemnification undertaking together with the amount or criteria determined by the Board of Directors to be reasonable in the given circumstances;
|
133.2. |
reasonable litigation expenses, including legal fees, paid for by the Office Holder, in an investigation or proceeding conducted against such Office Holder by
an agency authorized to conduct such investigation or proceeding, and which investigation or proceeding: (i) concluded without the filing of an indictment (as defined in the Companies Law) against such Office Holder and without there having
been a monetary liability imposed against such Office Holder in lieu of a criminal proceeding (as defined in the Companies Law); (ii) concluded without the filing of an indictment against such Office Holder but with there having been a
monetary liability imposed against such Office Holder in lieu of a criminal proceeding for an offense that does not require proof of criminal intent; or (iii) involves financial sanction;
|
133.3. |
reasonable litigation expenses, including legal fees, paid for by the Office Holder, or which the Office Holder is obligated to pay under a court order, in a
proceeding brought against the Office Holder by the Company, or on its behalf, or by a third party, or in a criminal proceeding in which the Office Holder is found innocent, or in a criminal proceeding in which the Office Holder was convicted
of an offense that does not require proof of criminal intent; and
|
133.4. |
any other event, occurrence or circumstances in respect of which the Company may lawfully indemnify an Office Holder of the Company (including, without
limitation, indemnification with respect to the matters referred to under Section 56h(b)(1) of the Israeli Securities Law 5728-1968, as amended.
|
133.5. |
The Company may undertake to indemnify an Office Holder as aforesaid: (i) prospectively, provided that the undertaking is limited to categories of events which
in the opinion of the Board of Directors can be foreseen when the undertaking to indemnify is given, and to an amount set by the Board of Directors as reasonable under the circumstances, and (ii) retroactively.
|
134. |
Subject to the provisions of the Companies Law including the receipt of all approvals as required therein or under any applicable law, the Company may, to the
maximum extent permitted by the Companies Law, exempt and release, in advance, any Office Holder from any liability for damages arising out of a breach of a duty of care towards the Company.
|
135.1. |
Any amendment to the Companies Law adversely affecting the right of any Office Holder to be indemnified or insured pursuant to Articles 132, 133 and 134 and any
amendments to Articles 132, 133 and 134 shall be prospective in effect, and shall not affect the Company’s obligation or ability to indemnify or insure an Office Holder for any act or omission occurring prior to such amendment, unless
otherwise provided by applicable law.
|
135.2. |
The provisions of Articles 132, 133 and 134 are not intended, and shall not be interpreted so as to restrict the Company, in any manner, in respect of the
procurement of insurance and/or in respect of indemnification and/or exculpation, in favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an
Office Holder; and/or any Office Holder to the extent that such insurance and/or indemnification is not specifically prohibited under law.
|
136. |
Should the Company be wound up and the assets of the Company made available for distribution among Shareholders be insufficient to repay all of the Company’s
paid-up capital, such assets shall be divided in a manner whereby the losses shall, as far as possible, be borne by the Shareholders pro rata to the nominal value of the paid-up capital on the shares held by each of them, and, if at the time
of the winding-up, the property of the Company available for distribution among the Shareholders should exceed the amount sufficient for the repayment of the full nominal value of the paid-up capital at the time of commencement of the
winding-up, the surplus shall be distributed to the Shareholders pro rata to the paid-up capital held by each of them.
|
137. |
Upon the sale of the Company’s assets, the Board of Directors may, or in the case of a liquidation, the liquidators may, if authorized to do so by a Resolution
of the Company, accept fully or partly paid-up shares, or securities of another company, Israeli or non-Israeli, whether in existence at such time or about to be formed, in order to purchase the property of the Company, or part thereof, and
to the extent permitted under the Companies Law, the Board of Directors may (or in the case of a liquidation, the liquidators may) distribute the aforesaid shares or securities or any other property of the Company among the Shareholders
without realizing the same, or may deposit the same in the hands of trustees for the Shareholders, and the General Meeting by a Resolution may decide, subject to the provisions of the Companies Law, on the distribution or allotment of cash,
shares or other securities, or the property of the Company and on the valuation of the aforesaid securities or property at such price and in such manner as the Shareholders at such General Meeting shall decide, and all of the Shareholders
shall be obliged to accept any valuation or distribution determined as aforesaid and to waive their rights in this regard, except, in a case in which the Company is about to be wound-up and is in the process of liquidation, for those legal
rights (if any) which, according to the provisions of the Companies Law, may not be changed or modified.
|
138. |
(a) Unless the Company consents in writing to the selection of an
alternative forum, with respect to any causes of action arising under the Securities Act of 1933 as amended, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint
asserting a cause of action arising under the Securities Act of 1933, as amended, against any person or entity, including such claims brought
against the Company, its directors, officers, employees, advisors, attorneys, accountants, or underwriters; and (b) unless the Company consents in writing to the selection of an alternative forum, the Tel Aviv
District Court shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of
the Company to the Company or the Company’s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Israeli Companies Law 5759-1999 or the Israeli Securities Law 5728-1968. Any person or entity
purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to these provisions.
|
• |
amendments to our articles of association;
|
• |
appointment or termination of our auditors;
|
• |
appointment of external directors;
|
• |
approval of certain related party transactions;
|
• |
increases or reductions of our authorized share capital;
|
• |
a merger; and
|
• |
the exercise of our board of directors’ powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c. |
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d. |
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that
has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the company’s ability to record, process, summarize and report financial information; and
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial
reporting.
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that
material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
c. |
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d. |
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that
has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to
adversely affect the company’s ability to record, process, summarize and report financial information; and
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial
reporting.
|